The 12-month total prevalent cases of migraine in the seven major markets (*7MM) are expected to increase from 72.7 million cases in 2020 to 73.7...
Hutchmed (China) Limited’s Orpathys (savolitinib) is now launched in China for patients with lung cancer and MET exon 14 skipping alterations that have progressed following...
As pharma companies continue to scale up digital transformation processes, a survey by GlobalData has highlighted that teaming up with experienced external vendors is driving innovative...
The approval of Roche / Chugai Pharmaceutical’s Evrysdi (risdiplam) as the first ever oral therapy in Japan for the treatment of spinal muscular atrophy (SMA)...
The type 2 diabetes (T2D) treatment landscape in Australia is mature with the availability of generics, insulin biosimilars and novel therapies. In this competitive market,...
Achieving glycemic control and managing hypoglycemia are two of the largest unmet needs in the treatment of Type 1 Diabetes (T1D), according to GlobalData. The...
Artificial intelligence (AI) and big data will play a major role in optimizing pharmaceutical drug discovery and development process, as indicated by 24% and...
Following the ADA update of the bacillus Calmette-Guerin (BCG) vaccine as a treatment for type 1 diabetes (T1D) earlier this month, leading data and analytics...
New immunotherapy agents in the oncology pipeline aim to predict the most important tumor antigens and formulate a personalized vaccine against them. With multiple catalysts...
Seelos Therapeutics has recently announced that the first patient has been dosed in the second part of its registrational study of SLS-002 (intranasal racemic ketamine)...
Eli Lilly and Novo Nordisk will continue to compete over the glucagon-like peptide 1 receptor agonist (GLP-1RA) market, with the strong possibility that the two...
Microbiome is a space with high potential, a fact underlined by the complete absence of microbiome-targeting treatments on the market. This therapeutic area is set...
The adult epilepsy market is expected to grow from $5.82bn in 2020 to $8.35bn by 2030 across the seven major markets (7MM*) at a compound...
The migraine treatment landscape in Japan is growing with the recent approval of calcitonin gene-related peptide (CGRP) inhibitors as preventative treatment. In this developing market,...
Corticosteroids are typically the first line of therapy for most patients with uveitis as these drugs are very effective and have anti-inflammatory effects. However, as...
The 2020 Olympic Games in Tokyo will take place from July 23 to August 8, 2021, with a one-year delay due to the COVID-19 pandemic;...
Over the past decade, disease-modifying cystic fibrosis transmembrane conductance regulator (CFTR) modulators have transformed the treatment paradigm for CF, according to GlobalData, greatly improving the...
Topical Janus kinase (JAK) inhibitors are becoming a major force in the atopic dermatitis (AD) space. An increasing number of JAK agents are filling the...
Following the news that Zydus Cadila has applied for emergency use authorization (EUA) to the Drug Controller General of India (DCGI) for its plasmid DNA...
Ardelyx presented interim data from its ongoing OPTIMIZE study at the European Renal Association. The primary endpoint of the Phase IV OPTIMIZE study is to...
The Olympic games are considered to be the world’s most prestigious sports competition, with more than 200 nations participating. However, this year’s Olympic games are...
Eisai and Biogen’s lecanemab (BAN2401) and Eli Lilly’s donanemab have recently received breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA) for...
UniQure recently announced the enrolment of the first two patients in the second cohort of a Phase I/II clinical trial of AMT-130, a micro ribonucleic...
Following today’s news (29 June) that Merck & Co’s Keytruda received EMA approval for patients with esophageal cancer (EC) or HER2-negative gastroesophageal junction (GEJ) adenocarcinoma...
Following the news that cases of COVID-19 due to the Delta variant in the UK have increased, despite record numbers of people being vaccinated; Emily Martyn,...
The Food and Drug Administration (FDA)’s Endocrinologic and Metabolic Drugs Advisory Committee voted in favor of Provention Bio’s teplizumab 10-7 to delay the onset of...
Untapped potential within the overactive bladder (OAB) market remains considerable due to under-diagnosis and under-treatment of this highly prevalent condition, according to GlobalData, a leading...
The diagnosed prevalent cases of uveitis in the nine major markets (*9MM) are projected to increase from 1.7 million cases in 2019 to 1.9 million...
Sage Therapeutics and Biogen have recently announced positive results from a pivotal Phase III trial for their novel, GABA A receptor allosteric modulator, antidepressant zuranolone....
The Tokyo Olympics will likely be an epicenter of transmission for COVID-19 and could increase variant of concern (VOC) spread, bringing new cases to Japan...
Gene therapies will provide a valid treatment option for patients that have developed resistance to chemotherapies across several cancer indications. With patient access set to...
China’s Bio-Thera Solutions has recently initiated a Phase III trial of its proposed golimumab biosimilar BAT2506 in China and Eastern Europe. Against this backdrop, BAT2506...
Chinese biopharma companies are eyeing strategic collaborations with western counterparts to leverage their extensive networks and commercial capabilities to promote indigenously developed drugs in China,...
CARsgen Therapeutics’ novel pipeline therapy for advanced hepatocellular carcinoma (HCC) stands out in the American Society of Clinical Oncology (ASCO) virtual annual meeting for being...
The non-small cell lung cancer (NSCLC) treatment landscape in Japan looks very mature with multiple drugs approved for targeted therapy, immunotherapy and chemotherapy. In this...
China has made its latest patent amendments effective from June 01, 2021, reforms which are likely to ensure protection against untimely and unfair generic competition....
Companies and organizations continue to report clinical trial disruptions across the globe due to the COVID-19 pandemic. These disruptions are being caused by a number...
26% of all cell and gene therapies in late-stage development in the US are being developed for oncology. The FDA has backed the use of CAR-T...
Since COVID-19 was officially declared a pandemic by the World Health Organization (WHO), the peak in total number of clinical trials for the virus was...
Preliminary safety results from the Oxford led Phase II Com-COV trial investigating immune responses in patients given heterologous prime-boost vaccine schedules indicate that mixing vaccines...
The COVID-19 pandemic saw certain markets such as anesthesia and respirator devices grow in 2020, while many others such as dental devices stagnated or saw...
The post-marketing data in the treatment refractory population of the COSMOS Phase IIIb study could allow J&J the opportunity to position interleukin (IL)-23 inhibitor Tremfya...
Following FDA’s approval of Aduhelm (aducanumab) for the treatment of Alzheimer’s Disease (AD), after no new drug for this indication has been approved in the...
Eli Lilly’s highly anticipated tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able...
The diagnosed prevalent cases of systemic sclerosis (SSc) in the seven major markets (*7MM) are projected to increase from 171,000 cases in 2020 to 187,000...
At the 70th annual American College of Cardiology (ACC) 2021 meeting, positive data from the EXPLORE-HCM trial was presented for Bristol-Myers Squibb’s mavacamten, a targeted...
Cadila Healthcare Ltd. is among the leading players in India which focuses on bringing in-house developed innovative therapies for patients. Cadila Healthcare has developed a...
Improved efficacy for HNSCC therapeutics able to demonstrate an overall survival benefit remains a key unmet need in the indication. The next decade may...
Following the news of Medtronic's latest financial report for Q3 FY2021 that medical device revenues have fully recovered through the anniversary of the COVID-19 pandemic,...
Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the...
Boehringer Ingelheim recently announced that its product, BI 425809, has received Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for Cognitive...
The UK regulatory review of Alexion Pharmaceuticals acquisition by AstraZeneca limits the ability of GlaxoSmithKline (GSK) to buy its way out of a proxy brawl...
Substance use rose by 13% in the US during 2020, which could result in an additional 252,000 cases in the number of Americans who abuse...
The neuropathic pain market is the most valuable segment within the pain indications and was valued at $10.8bn in 2020 globally. It is forecast to...
Annovis Bio recently announced positive results from a Phase IIa trial of its pipeline asset ANVS401 (posiphen) in patients with early Parkinson’s disease (PD). The...
NLS Pharmaceutics has recently announced new data confirming that its narcolepsy product, a controlled release (CR) formulation of mazindol, has agonist activity at orexin-2 receptors...
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain...
The multiple sclerosis (MS) therapeutics market is becoming increasingly crowded, but the overall fulfillment of unmet needs is medium. There are no curative therapies for...
Therapies targeting B-cell maturation antigen (BCMA) now account for approximately 10% of immuno-oncology drugs in Phase I-III development globally. With just two marketed agents available...
At the 70th annual American College of Cardiology (ACC) 2021 meeting, results were presented for the PARADISE-MI trial. The results demonstrate that for Novartis to...
Following Arcutis Biotherapeutics’ announcement of new data from its pivotal DERMIS-1 and DERMIS-2 studies of topical phosphodiesterase-4 (PDE4) inhibitor roflumilast for plaque psoriasis (PsO) at...
Prior to the COVID-19 pandemic, the diagnosed prevalence of type 1 diabetes (T1D) was predicted to grow annually by 0.93% in the US, and the...
Japanese pharmaceutical company Daiichi Sankyo received a major headway in the global oncology space with the launch of its first antibody drug conjugate (ADC) therapy...
While post-Brexit regulatory changes continue to cause significant uncertainty for the UK’s healthcare sector, the UK Government’s initiatives, such as the Medicines and Medical Devices...
The ankylosing spondylosis (AS) treatment landscape in India is moderately established with a few disease-modifying anti-rheumatic drugs (DMARDs) available from innovator companies along with biosimilars...
Vertex, the current owner of the entire cystic fibrosis transmembrane conductance regulator (CFTR) modulators’ market share, is expected to remain the market leader over the...
Diagnosed incident cases of endometrial cancer are expected to increase from 120,883 cases in 2020 to 133,690 in 2030 in the eight major markets (8MM*),...
India could reach approximately 1.4 million new daily COVID-19 cases by May 24, if current transmission risk is not reduced further, according to a two-week...
Over the past 20 years, the diabetes market has gone through significant maturation as a result of increased innovation and modernization of therapeutic treatments. The...
Following today’s news (18 May) that Bristol-Myers Squibb (BMS) has exclusively licensed Agenus’ bispecific anti-TIGIT antibody, AGEN1777, for up to $1.36bn; Sakis Paliouras, PhD, Senior Oncology...
While the UK-EU Trade and Cooperation Agreement (TCA) removed the prospect of a no-deal Brexit, it introduced a wide range of changes to the UK’s...
With pipeline approvals of varying mechanisms and an influx of newly diagnosed patients, the chronic kidney disease (CKD)-hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) market...
Following the news that cases of the Indian variant in the UK has tripled in one week during the same period lockdown rules are due...
GlobalData has partnered with BizInt Solutions for reporting drugs and clinical trials data from its Pharma Intelligence Center. BizInt Smart Charts software is used to...
Celiac disease (CD) represents an area of high unmet clinical need as there are no products that have been approved specifically for this indication. Historically,...
Following the news that the US Food and Drug Administration (FDA) has authorized Pfizer and BioNTech’s Comirnaty for adolescents 12 to 15 years of age,...
The Food and Drug Administration’s (FDA) accelerated approval program has recently come under fire due to high-profile withdrawals of immune checkpoint inhibitors (ICIs) from the...
The Food and Drug Administration (FDA) approved more biologic new molecular entities (NMEs) in 2020 than in any other year in the previous decade, while...
More than 50% of surveyed healthcare industry professionals from Europe believe that Brexit allowed the UK to accelerate its COVID-19 vaccines approval process 31% of...
In 2020, 92% of 5EU physicians stated that they used biosimilars in at least 25% of their RA patients, compared to 70% of physicians...
Diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets (7MM*) combined is expected to increase from 8.57 million cases in 2020...
Merck & Co. and Bristol-Myers Squibb (BMS) have transformed the treatment paradigm in advanced and metastatic head and neck squamous cell carcinoma (HNSCC) settings by...
Following the news that Roche has received emergency use authorization (EUA) for a COVID-19 antibody cocktail casirivimab and imdevimab; Prashant Khadayate, Pharma Analyst at GlobalData, a...
The hepatocellular carcinoma (HCC) market is expected to grow from $1bn in 2019 to $5.3bn in 2029 in the eight major markets (8MM*) at a...
Thermo Fisher Scientific, a diversified life science company, has announced its intent to purchase PPD, a Clinical Research Organization (CRO), for $17B. PPD is a...
The surge in new variants for COVID-19 and an increase in subsequent cases is continuing to have an impact on clinical trials, while still allowing...
A post hoc analysis of the multicenter AMETHYST-DN study found that the use of Vifor Pharma’s Veltassa (patiromer) significantly reduced serum potassium in patients ages...
Freeline Therapeutics recently announced plans to progress dose escalation for its Phase I/II trial for FLT190, an adeno-associated variant (AAV) based gene therapy for Fabry...
China has reformed its regulatory system in recent years to include various fast-track programs similar to the US, EU, and Japan to incentivize the development...
Drugs being developed for COVID-19 were awarded the highest number of SBIR/STTR funding grants, at 187 grants. Most grants awarded to drugs that are currently...
The market landscape in the nine major markets (9MM*) for chronic hepatitis B (CHB) is expected to see significant change between 2019 and 2029. Projected...
It is expected that 15 therapeutics will launch in the Type 1 Diabetes (T1D) market in the eight major markets (8MM*) before 2030. They include...
COVID-19 infections continue to rise with several countries facing second-and third-wave infections with the newly evolved mutant strains, thereby increasing the demand for effective vaccines....
Although cell therapies such as CAR-T have been approved and used successfully to treat hematological cancers, there are currently no cell therapies approved for the...
As COVID-19 cases continue to soar in some countries, demand for Pfizer and Moderna’s vaccines is fast exceeding production capabilities, while restrictions placed on AstraZeneca...
The COVID-19 pandemic brought not just a more difficult business environment to operate in, but also opportunities for contract manufacturing organizations (CMOs), as even the...
The melanoma market has experienced moderate growth since 2016, and is expected to increase further, from $5.59bn in 2019 to $7.42bn in 2029 across the...
The Parkinson’s disease (PD) market is expected to see significant growth in the 7MM*, with the decade starting 2019 seeing an impressive 12.6% compound annual...
The burden of diagnosed small cell lung cancer (SCLC) is expected to increase at an annual growth rate (AGR) of 3.5% from around 180,000 cases...
In early April, AbbVie announced its submission to the US FDA for its selective interleukin (IL)-23 inhibitor, Skyrizi (risankizumab), for the indication of psoriatic arthritis...
Despite considerable improvements that blockchain could bring to the pharmaceutical sector, this technology-related revolution has not quite happened yet. While COVID-19 accelerated digital transformation in...
Australia has the highest age-standardized incidence rate for all cancers in the world and one of the countries with substantial cancer screening programs. Against this...
Following today’s news (26 April) that the Food and Drug Administration (FDA) has accepted Axsome Therapeutics’ new drug application (NDA) for its novel antidepressant therapy...
A novel ‘double mutant’ variant of SARS-CoV-2, along with other factors, has accelerated the COVID-19 pandemic in India, setting a global record of new daily...
The pancreatic cancer market has seen the launch of premium priced therapies in the last three to four years in late-stage pancreatic cancer patients, resulting...
Beijing-based pharmaceutical company Sinovac Biotech’s CoronaVac vaccine was recently found to be 49.6% effective in real-world data from Brazil. However, considering the global demand for...
The emergence of new SARS-CoV-2 variants have been detected in over 40 countries and are disrupting drug development worldwide. The prevalence of these more transmissible...
The commercial launch of Urovant Sciences’ first product, Gemtesa (vibegron), a beta 3 adrenergic receptor agonist in the US, addresses overactive bladder (OAB) symptoms by...
Abbott’s rapid COVID-19 antigen self-test, the BinaxNOW, is now widely available across the US at CVS Pharmacy, Walgreens, and Walmart without a prescription; Dara Lo, Medical...
Diagnosed incident cases of melanoma in the eight major markets (8MM*) combined is expected to increase from 0.19 million cases in 2019 to 0.22 million...
With the Sputnik V vaccine’s recent approval, India now has three vaccines authorized for COVID-19 treatment. However, despite better efficacy over Serum Institute of India/...
Immuno-oncology (IO) agents will be the dominant class in the hepatocellular carcinoma (HCC) market by 2029 due to the launch of pipeline drugs targeting programmed...
Following today’s news (16 April) that Amgen has completed its planned acquisition of Five Prime Therapeutics for $1.9bn; Sakis Paliouras, PhD, Senior Oncology & Hematology Analyst...
Five delays in regulatory reviews for a single drug class in less than one month could serve as an early warning sign that the Food...
Pfizer/BioNTech’s Comirnaty (tozinameran) is forecast to have peak sales of $24.8bn by 2021, which is only its second year on the market. This is a...
Chinese domestic ICI brands poised for approvals across multiple oncology indications International brands seeking access in China should balance diminishing drug prices with the...
Following Roche’s announcement of new 2-year data from Part 2 of FIREFISH, a Phase II/III global study evaluating Evrysdi (risdiplam) in infants aged 1-7 months...
The University Technology Licensing Program (UTLP) was created to improve innovation in multiple sectors and facilitate more efficient licensing between commercial companies and the 15...
The approval of a Food and Drug Administration (FDA) emergency use authorization (EUA) for AstraZeneca’s COVID-19 vaccine AZD1222 will boost confidence and use of the...
The rheumatoid arthritis (RA) treatment landscape in Australia is well established with several novel disease-modifying anti-rheumatic drugs (DMARDs). However, stiff biosimilars competition is expected to...
The number of diagnosed prevalent cases of Parkinson’s disease is expected to rise in the seven major markets (7MM), which comprises the US, France, Germany,...
Following the news that the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) released a joint statement calling...
Primary research by data and analytics company GlobalData has revealed that 80% of asthma patients do not take their medication effectively. The reasons for this...
Given recent findings that nearly one-third of previously hospitalized COVID-19 patients in the UK are readmitted for further treatment within five months after infection, and...
The inherent heterogeneity of diseases such as cancer is driving the field of personalized (precision) therapies. Within personalized therapies, chimeric antigen receptor (CAR-T) therapies are...
Key opinion leaders (KOLs) in the US, 5EU* and China have confirmed that they are not satisfied with the current state of surveillance programs for...
There are diverse development strategies and trends in the Parkinson’s disease (PD) treatment at present, however only a few of them address the pressing need...
The burden of diagnosed chronic hepatitis B (CHB) is expected to increase at an annual growth rate (AGR) of 0.20% from an estimated 17.8 million...
Following the news that the European Medicines Agency (EMA) has confirmed a possible link between very rare cases of unusual blood clots after vaccination with...
Novavax’s investigational COVID-19 vaccine, NVX-CoV2373, is forecast to have $33.3bn total sales for 2021–2027 and to be the second-leading vaccine candidate by peak forecast sales...
Diagnosed prevalent cases of type 1 diabetes (T1D) in the eight major markets (8MM*) combined are expected to increase from 3.33 million cases in 2019...
The US is running the highest number of COVID-19 clinical trials in the world, according to the clinical trial database by data and analytics company...
Emergent BioSolutions has been one of the largest winners from the contract manufacturing of COVID-19 vaccines but, having ruined 15 million doses of J&Js COVID-19...
Immuno-oncology (IO) agents, particularly immune checkpoint inhibitors (ICIs) and CAR-T cell therapies, have extended the survival of patients in many cancer types and current investigational...
The major depressive disorder (MDD) market is expected to grow from $3.97bn in 2019 to $7.87bn by 2029 across the eight major markets (8MM*) at...
The coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences for the mental health of women with major depressive disorder (MDD), which is expected...
Newron Pharmaceuticals and Zambon’s planned pivotal trial to evaluate a label extension for Xadago (safinamide) in patients with Parkinson’s disease levodopa-induced dyskinesia (PD-LID) is a...
Driven by technical advancements and increasing prevalence of cataracts and refractive error with aging populations, the intraocular lenses (IOLs) market was worth nearly $3.5bn in...
Following the news that the European Medicines Agency (EMA) has approved Novartis’ Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in...
Non-alcoholic fatty liver disease (NAFLD) is emerging as an important cause of a wide spectrum of liver diseases including non-alcoholic steatohepatitis (NASH) in India. A...
Following today’s news (30 March) that the FDA has accepted AbbVie’s new drug application for atogepant for the preventive treatment of migraine; Christie Wong, Pharma Analyst...
With the expected decrease in monthly COVID-19 cases due to increasing vaccinations in countries such as the US and the UK, leading data and analytics...
According to GlobalData’s clinical trial database, the landscape for endometriosis has greatly diversified in recent years. The number of companies initiating trials in the space...
Negative CAGRs of 0.61% and 3.89% is projected for the chemotherapy drug class in the US market for haematological and solid tumors, respectively. Sales...
Western China’s pharmaceutical production needs international and domestic investment, as there less number of facilities compared to other Chinese regions and few international pharma companies...
The latest wave of COVID-19 vaccines - those from AstraZeneca and Johnson & Johnson (J&J) - are recombinant vector vaccines, which are a different molecule...
Rising strategic partnerships between global pharmaceutical companies to develop therapies in the head and neck cancer space can serve as opportunities for increased scientific development...
Texas and several other states such as Mississippi, Louisiana, and Michigan rescinding previous executive orders that were intended to slow the spread of COVID-19 could...
The total chronic kidney disease (CKD) anemia drug market size for the 8MM* in 2019 was valued at $4.7bn, defined as sales of major branded...
Australia continues to focus on reducing healthcare expenditure and encouraging the use of biosimilars over their reference product. Cipla adopted deals route to capitalize on...
On March 7, 2021, the UK reported 5,265 daily confirmed cases, the lowest reported case count since the second-wave peak of over 68,000 cases on...
The field of immuno-oncology (IO) has been in need of novel biomarkers ever since 2011. The most promising or anticipated biomarker among high-prescribing physicians in...
Following the news that the European Medicines Agency (EMA) has approved Kixelle, Biocon/Mylan’s biosimilar of Novo Nordisk’s Novolog/NovoRapid (insulin aspart); Samisha Khangaonkar, Pharma Analyst at GlobalData,...
At the one-year anniversary of the World Health Organization’s official declaration of the COVID-19 pandemic, there has been record-breaking progress made towards developing a COVID-19...
Clustered regularly interspaced short palindromic repeat (CRISPR) therapies are one of the most potentially powerful and transformative technologies in human history, according to GlobalData, a...
The diagnosed prevalent cases of chronic kidney disease-anemia (CKD-anemia) in the eight major markets (*8MM) are projected to increase from four million cases in 2019 to...
Italy and France are witnessing another wave of COVID-19 infections probably caused by the spread of the UK B.1.1.7 variant and the only realistic solution...
High value deals have dominated the Asia-Pacific (APAC) pharmaceutical strategic partnership landscape in 2020. Within the region, China is well ahead of other countries, particularly...
The COVID-19 vaccination rate in the UK exceeds that of any other country in Europe and is on track to be the first country in...
Roche recently announced that its product, Evrysdi (risdiplam), which was approved by the US Food and Drug Administration (FDA) in August 2020, was recommended for...
The 12-month prevalent cases of major depressive disorder (MDD) is expected to increase from 53.37 million cases in 2019 to 55.36 million cases in 2029,...
Over a quarter of rare diseases trials were terminated between 2016 and 2020* due to low accrual rates, according to research by GlobalData, a leading...
If new SARS-CoV-2 variants continue to develop, they could affect not only the effectiveness of COVID-19 vaccines, but also the natural immunity that COVID-19 survivors...
The hepatitis C virus (HCV) therapeutics market in Japan is highly competitive with stiff competition between Gilead and AbbVie. However, AbbVie has taken an edge...
AstraZeneca/Medimmune Therapeutics’ Imfinzi (durvalumab), an immunotherapy targeting programmed death-ligand 1 (PD-L1), recently failed to demonstrate increased overall survival (OS) in patients with recurrent or metastatic...
Following Galapagos’ announcement of pooled interim results from its ongoing MANTA and MANTA-RAy safety studies for Jyseleca (filgotinib); Rose Joachim, Pharma Analyst at GlobalData, a leading...
During Colorectal Cancer Awareness month, it is important to highlight that precision medicine approaches are gaining traction in this indication. Positive results from any of...
The Trump administration’s decision to relax oversight of genetically modified (GM) animals for food prioritizes big businesses and the livestock industry, while overriding FDA scientists...
Following the news that Bharat Biotech’s COVID-19 vaccine Covaxin showed 81% interim efficacy; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers...
In February 2021, Novo Nordisk released impressive data from its Phase IIIa STEP1 trial for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in a bid...
With the COVID-19 pandemic recently passing one year in duration, clinical research continues to be significantly affected. Sponsors have had to modify trial designs to...
Following the news of President Biden’s announcement that the US will have enough COVID-19 vaccine supply for all US-Americans by the end of May; Philipp Rosenbaum,...
Even though the pharmaceutical sector used to display a more conservative stance toward the adoption of new technologies, the COVID-19 pandemic acted as a trigger...
The Central Drugs Standard Control Organization (CDSCO) has recently approved several generic versions of sunitinib to treat kidney cancer. Against this backdrop, the approval of...
The approval of Roche's Avastin (bevacizumab) plus Tecentriq (atezolizumab), in addition to the long list of pipeline products, opens up gaps in the treatment paradigm...
The number of clinical trials disrupted by the COVID-19 pandemic continues to increase into 2021, although the degree of disruption varies depending on the therapy area, says GlobalData, a leading data and analytics company. Scotty Chung-Siu, MPH, Senior Analyst at...
Innovative drug approvals increased in the US between 2019 and 2020. This increase happened despite the FDA’s stretched resources, as it had to reassign staff to cope with COVID-19-related activities. The agency approved 121 novel drugs in 2020, compared with 119 in in 2019, says GlobalData,...
While the US has excelled in vaccine development, its distribution and administration efforts did not go according to plan due to the dependence on states....
National Colorectal Cancer (CRC) Awareness Month is an opportunity to raise awareness about the disease and educate patients, especially about recurrence, one of the most...
The market performance of the top 20 Bio/Pharma companies is still being impacted by the COVID-19 pandemic, either positively for companies developing a vaccine for the disease or negatively for those working on a treatment, says GlobalData, a leading data and analytics company. Madeleine Roche, MSc, Analyst...
As pharmaceutical companies continue to grapple with issues ranging from lack of transparency on pricing, price gouging to questionable ethical practices and clinical data reporting processes, addressing environmental, social, and governance (ESG) issues will continue to be an...
The diagnosed prevalent cases of human immunodeficiency virus (HIV) in the seven major markets (7MM*) are projected to increase from 1.87 million in 2019 to...
Velphoro’s (sucroferric oxyhydroxide) recent VELREAL multicenter study showed a 20% decrease in serum phosphorus in addition to reduced parathyroid hormone level in chronic kidney disease...
The recent SARS-CoV-2 virus variant in South Africa (B.1.351) underscores a critical weakness in combatting the COVID-19 epidemic and may prolong it indefinitely, says GlobalData,...
The Parkinson’s disease (PD) pipeline has been hit significantly with a string of failures among its most anticipated mid-stage pipeline candidates. This news presents a...
The human immunodeficiency virus (HIV) therapeutics market was worth an estimated $22.9bn across the seven major markets (7MM*) in 2019. The market is expected to grow at a Compound...
Gilead and Galapagos recently announced the discontinuation of the ISABELA Phase III clinical trials investigating ziritaxestat, a once daily autotaxin inhibitor formerly known as GLPG-1690,...
China-based EOC Pharma has recently entered an in-licensing partnership with US-based biopharmaceutical company Aadi Bioscience for the development and commercialization of ABI-009 (Fyarro). This deal,...
Caladrius Biosciences’ initiation of the Phase IIb FREEDOM trial of its autologous CD34+ stem cell therapy, CLBS16, in coronary microvascular dysfunction (CMD), is an important development milestone. While concerns regarding the therapy’s scalability, potential cost and...
As of 2020, unmet needs in immuno-oncology (IO) revolve around three main pillars: Cost, efficacy and toxicity. While a multitude of pipeline agents are poised...
The need to develop novel innovative cancer drugs at affordable prices is forcing large pharmaceutical firms to collaborate with biotech companies and academic institutions. Japan-based...
Over 60% of diagnosed prevalent cases of lupus nephritis in the UK in are seen in class IV and V, says GlobalData, a leading data...
Through the Brexit deal struck between the UK and EU on 24 December 2021, the UK will be part of Horizon Europe, the EU’s next framework...
If Tidepool’s diabetes management app Tidepool Loop gains its 510(k) clearance from the Food and Drug Administration (FDA), it will have a significant impact on...
COVID-19 relief and vaccine roll-out should prioritize American Indians and Alaska Natives (AI/AN) populations, as they are a marginalized group in the US healthcare and...
Janssen Pharmaceuticals has recently partnered with Verana Health, which is specialized in data analytics in the field of ophthalmology and urology. The collaboration can help...
The FDA and EMA’s recent positive opinions on the expanded use of Merck & Co’s Keytruda (pembrolizumab) has the drug all set to catch up...
Many clinical trials were set to resume activity as the initial peak of the COVID-19 virus started declining. However, with the number of confirmed COVID-19...
The primary analysis of AstraZeneca/Oxford’s vaccine is likely to put pressure on other companies to demonstrate reductions in transmission as soon as possible, says GlobalData,...
Experts estimate that achieving herd immunity to COVID-19 will required upwards of 70–90% of the population to have immunity. While vaccine efficacy for Moderna’s mRNA-1273...
The recent deal between Coherus BioSciences and Shanghai Junshi Biosciences for Junshi’s PD-1 inhibitor named Tuoyi (toripalimab) is the fifth such deal between the US...
India has reported a gradual decline of the COVID-19 infections after reporting a high number of daily new cases in September and October 2020. The...
In its Union Budget 2021, India has more than doubled its spending on healthcare to boost the sector which has been strongly impacted by the...
Biogen recently announced Food and Drug Administration (FDA) approval of its new intramuscular (IM) injection route of administration for Plegridy (peginterferon beta-1a) for the treatment...
While governments are ramping up vaccination programs, continued research into the effectiveness of the vaccines is imperative to prevent a worsening of the impact of...
Manufacturing and logistic disruptions worldwide are affecting the distribution of COVID-19 vaccines, including Novasep’s site cutting AstraZeneca vaccine production by 60%, an upgrade at Pfizer’s...
With the COVID-19 pandemic contributing to delays in clinical trial enrollment and routine cancer screening and treatment, many barriers have arisen preventing patients from seeking...
The implementation of new strategies will turn the hepatocellular carcinoma (HCC) market into a land of opportunity for manufacturers, leading to a wave of new...
Tonix Pharmaceuticals (Tonix) has recently announced a licensing deal with Katana Pharmaceuticals for its intranasal potentiated oxytocin with a view to expand its application into...
Brazil has been among the most heavily affected countries in Latin America during the COVID-19 pandemic, and it remains among the top three worst affected...
There has been a boom in bio/pharma special purpose acquisition companies (SPAC) deals in recent years. Last year seems to be no different as SPAC...
President Joe Biden brings a significant likelihood of federal marijuana reform, one of his key campaign promises. Amidst the ongoing opioid crisis, legalizing cannabis at...
The emergency use approval (EUA) of Covaxin in India will further strengthen its credibility and validate Bharat Biotech’s intent to make the indigenous vaccine popular...
Sonder’s European expansion plans have not been halted due to COVID-19 as the company is now exploring the Spanish market, with a keen eye on Madrid and Barcelona. Sonder is in a position to expand...
Since June 2020, the number of total disrupted trials has been falling slowly; however, this has leveled off in October 2020. Despite this, the number of clinical trials that have resumed continues to rise. The majority...
• COVID-19 will continue to impact all aspects of the pharma value chain in 2021 • Drug development activities, in particular clinical trials, will have the biggest impact on industry...
Following the news that Concert Pharmaceuticals is stopping development of its adjunctive treatment for schizophrenia, CTP-692 (D-serine), after it failed to meet its primary endpoint...
There has been a 639% increase in the number of COVID-19 clinical trials worldwide, from 549 COVID-19 clinical trials in early April 2020 to over...
Following the news that Novavax’s COVID-19 vaccine shows 89.3% while Johnson & Johnson’s (J&J) demonstrated 66% efficacy; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology...
Following Pfizer’s recent announcement of co-primary endpoint results from ORAL Surveillance (NCT02092467) in rheumatoid arthritis (RA) patients with cardiovascular (CV) risk factors; Rose Joachim, Pharma Analyst at GlobalData, a leading data and...
Despite seriously affecting the ability to carry out clinical research, COVID-19 is also proving to be a catalyst that may transform the drug development process, with technological innovations taking center stage in driving this...
The melanoma therapeutics market in Japan comprises of drugs approved for chemotherapy, immunotherapy, and targeted therapy. Among these, immunotherapy and targeted therapy are the leading...
One the most concerning secondary conditions of COVID-19 is myocarditis and research indicates that 60% of COVID-19 survivors, independent of the severity of the illness,...
The rapid advancement of mRNA vaccine development in recent months - in an attempt to halt the COVID-19 pandemic - is expected to continue to...
The COVID-19 pandemic has shown the many wide-ranging benefits of telemedicine. In a survey by GlobalData, pharmaceutical industry professionals noted that they expect telemedicine to...
This year is expected to provide significant insights into the future of cervical cancer treatment since out of the 107 ongoing clinical trials worldwide for cervical cancer, 30% are estimated to be completed by the end of the year, says GlobalData, a leading data and analytics company. Miguel Ferreira, MSc,...
The asthma market was valued at $9.7bn in 2019 across the seven major markets (7MM*), and it is expected to grow to $10.8bn by 2029...
The pharmaceutical industry will be shaped by several emerging trends in 2021. The industry will need to adapt quickly post-COVID-19 by overcoming the spread of...
Forxiga’s (dapagliflozin) latest priority review by the FDA for chronic kidney disease (CKD) further signifies the drug’s major advantages over existing treatments and will provide...
Artificial intelligence (AI) will transform the pharmaceutical industry in the coming years by delivering productivity improvements and efficiencies across the entire pharma value chain, says...
Following the news that AriBio announced the completion of a Phase II clinical trial of AR1001; Sarah Elsayed, MBA, Neurology Analyst at GlobalData, a leading data...
Myovant Sciences’ deal with Pfizer to co-develop and commercialize oral GnRH antagonist relugolix in oncology and women’s health in the US and Canada will substantially...
Aldeyra Therapeutics recently announced top-line results from the run-in cohort of the Phase III trial evaluating its product 0.25% reproxalap for patients with dry eye...
South Korea has become the third country in the Asia-Pacific region after Japan and Australia to approve the first ever triple combination therapy from Novartis...
China updated its National Reimbursement Drug List (NRDL) in December 2020 to include 119 new medicines, with an average price cut of 50.64% agreed by...
REMD Biotherapeutics recently announced the top-line results of its Phase II study of volagidemab, which aimed to determine whether volagidemab could decrease daily insulin requirements...
Israel is currently on track to be the first country in the world to inoculate its entire population. This could provide a gold standard for...
Ongoing COVID-19 lockdowns and requirements of social distancing have swiftly pushed healthcare provision and patient monitoring towards remote options. Even though remote patient monitoring (RPM) was already being used...
Governments need to place more focus on South Africa’s COVID-19 variant, 501.V2, as it is now considered more infectious than the UK variant based on...
The UK January lockdown measures should decrease the number of COVID-19 cases in the following weeks, with the possibility of falling as low as approximately...
The Food and Drug Administration (FDA) recently accepted Pfizer and OPKO Biologics Biologics License Application (BLA) for somatrogon for the treatment of pediatric growth hormone...
The rheumatoid arthritis (RA) market is expected to grow from $26.2bn in 2019 to $29.1bn in 2029 across the eight major markets (8MM*) at a compound annual growth...
The immuno-oncology (IO) therapeutic area is increasingly becoming recognized as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy and other targeted treatments due...
The COVID-19 pandemic was initially typified with worldwide calls for more ventilators. The ventilators market was worth nearly $1.1bn before the pandemic and has surged...
Biogen recently announced the first SMA (spinal muscular atrophy) patient treated in a study Phase IV RESPOND that will evaluate the efficacy and safety of...
On the heels of the highest single-day death total in the UK, the need for speed in the mass vaccination program against COVID-19 has become...
Following the news that the incoming Biden administration promises $20 billion for a national vaccination program, Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData,...
Japan is aggressively making efforts to vaccinate its population for COVID-19 with a strong focus on signing pre-orders. The country has signed multiple deals with...
Serum Institute of India’s (SII) Covishield and Bharat Biotech’s Covaxin have recently received emergency use authorization (EUA) in India. However, despite indigenous vaccine Covaxin’s approval,...
The non-small cell lung cancer (NSCLC) market has grown significantly in recent years partly due to the introduction of immune checkpoint inhibitors (ICIs) into the...
The pancreatic cancer market has seen the launch of premium priced therapies in the last three - four years in late-stage pancreatic cancer patients, resulting in...
Technological advancements in oncology, such as the introduction of immuno-oncology therapies and targeted therapies, have improved quality of life (QoL) compared to conventional treatment options,...
Teva Pharmaceuticals and MedinCell are seeking to enter the long-acting injectable (LAI) schizophrenia market after their LAI mdc-IRM (risperidone ER) demonstrated a statistically significant increase...
The Japanese type 2 diabetes (T2D) therapeutics market is highly competitive with several generic, branded and biosimilar products available. Among the various types of therapies,...
Pfizer-BioNTech’s two-shot mRNA COVID-19 vaccine, BNT-162b2, is currently the leading prophylactic vaccine for COVID-19 based on forecast sales as it is expected to be the...
In 2021, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData,...
The diagnosed incident cases of hepatocellular carcinoma (HCC) in urban China are expected to increase by 44.41% over the next decade (2019-2029), according to GlobalData,...
Urban China is expected to have the highest number of diagnosed incident cases of non-small cell lung cancer (NSCLC) among the eight major markets 8MM*...
Up to December 1, 2020, mergers and acquisitions (M&A) deal value in the Bio/Pharma industry was down only 13% compared with last year, with a...
The World Health Organization (WHO) launched a global strategy on 17th November 2020 to eliminate cervical cancer. The move paves way for the prevention of...
As of November 30, 2020, the top reason for disrupted clinical trials is slow enrollment, which is causing delays in 49% of trials. The other...
The COVID-19 outbreak’s trajectory in Africa is expected to continue to increase for a prolonged period due to lower testing capacity and lack of vaccination...
A positive recommendation from an FDA Advisory Committee has set Novartis’ Entresto (sacubitril/valsartan) on track to become the first drug to be approved for the...
KBP Biosciences recently shared results for its BLOCK-CKD Phase IIb study and the positive trial results suggest KBP-5074 may become a viable competitor to the already established non-steroidal mineralocorticoid receptor antagonists (MRAs) for chronic kidney disease (CKD), according to GlobalData, a leading...
SoniVie and ReCor Medical both recently received US Food and Drug Administration (FDA) breakthrough device designation for their TIVUS and Paradise renal denervation systems. With...
NovoNordisk’s decision to investigate its recently launched Type 2 Diabetes (T2D) drug Rybelsus (semaglutide) in a pivotal Phase IIIa study of patients with early Alzheimer's disease may...
South Korea’s pharmaceutical sector is becoming increasingly innovative and attractive to foreign investment only 18 months into the government’s $1.7bn five-year biotech plan. The country’s...
The growing rate of new COVID-19 cases indicates the US is facing a major crisis of hospital shortages not yet seen in this pandemic, and...
The COVID-19 pandemic and the subsequent lockdown measures have led to the widespread adoption of telemedicine in India. Against this backdrop, the growing market can...
Following the news that the US Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for Roche’s Ocrevus (ocrelizumab) in patients with...
Novartis recently engaged in a flurry of collaborative agreements in the ophthalmology field and the scope of these collaborations will help the company to pull...
Juvenile Diabetes Research Foundation (JDRF) recently announced the launch of its ground-breaking screening initiative for type 1 diabetes (T1D), T1Detect, which aims to make early detection of T1D easier and more accessible to the broader population. This...
Following the news that the US Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for Roche’s Ocrevus (ocrelizumab) in patients with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS); Sarah...
The COVID-19 pandemic has pushed India to expedite focus on pharma research and development (R&D) to become more independent. The hope of getting indigenous COVID-19 vaccines...
The Japanese immunology market is highly competitive with many innovator products available for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), inflammatory bowel disease (IBD)...
The recently demonstrated superiority of AbbVie’s Rinvoq (upadacitinib) versus Regeneron and Sanofi’s Dupixent (dupilumab) across primary and all secondary endpoints in the Phase IIIb Heads Up study may well showcase its potential...
There are eight mRNA COVID-19 vaccine candidates currently in Phase II or Phase III clinical trials. These vaccines are faster to develop than traditional vaccine...
With a 2021 Food and Drug Administration (FDA) submission now on the cards, following impressive data from its pivotal trial HOPE-B, uniQure’s etranacogene dezaprvovec (EtranaDez)...
The overall level of unmet need in hepatocellular carcinoma (HCC) is high due to its severity and low survival. However, the needs will soon be...
Following the news that the US Food and Drug Administration (FDA) has recommended emergency approval for the Pfizer-BioNTech COVID-19 vaccine and that the US has...
Following Slovakia’s national testing program from 31 October – 1 November, where two-thirds of the population were tested and the number of new daily cases dropped substantially, Slovakia was applauded for its efforts and held...
With Pfizer/BioNTech’s COVID-19 vaccine becoming the first mRNA vaccine in the world to receive emergency use approval by the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA), the race is on for other bio/pharma companies with COVID-19 candidates to...
The lack of approved immune checkpoint inhibitors (ICI) in the gastric and gastroesophageal adenocarcinoma (G/GEJAC) market in the *5EU is expected to significantly enhance the...
Galapagos recently reported positive topline results from its Phase IIA PINTA clinical trial investigating the use of 100 mg GLPG1205 for the treatment of idiopathic pulmonary fibrosis (IPF). Although the trial had a promising...
Currently in the UK, there are over nine million lifetime diagnosed prevalent cases of asthma and approximately 13 million undiagnosed asthma patients, says GlobalData, a...
Lockdowns in the UK and some US states may be contributing to the slight slowing in the trajectory of ‘resumed’ trials, says GlobalData, a leading...
The diagnosed prevalent cases of rheumatoid arthritis (RA) in the eight major markets (*8MM) is expected to increase from 4.6 million cases in 2019 to...
Following the news that Janssen has submitted a Marketing Authorisation Extension to the European Medicines Agency (EMA) for its product paliperidone palmitate 6-Monthly (PP6M) for...
Two recent Phase III mRNA COVID-19 vaccine trials resulted in 95% efficacy and generally well-tolerated safety profiles for vaccines BNT162b2 and mRNA-1273, developed by Pfizer/BioNTech...
Following Prime Minister Justin Trudeau’s announcement of Canada’s vaccination schedules; James Spencer, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “With the...
Following recent news that the UK will become one of the first countries in the Western world to authorize a COVID-19 vaccine; Urte Jakimaviciute, Senior Director...
Following the news that Biogen have entered into a licensing agreement with Sage Therapeutics to jointly develop and commercialize zuranolone (SAGE-217) and SAGE-324; Philippa Salter, Neurology...
The field of regenerative medicine (RM) is rapidly expanding as there are currently 53 marketed RM products and 175 RM pipeline agents in development in...
Following the news that Pfizer/BioNTech’s COVID-19 vaccine BNT162b2 received emergency use approval from UK health authorities; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a...
The burden of diagnosed asthma is expected to increase at a compound annual growth rate (CAGR) of 0.31% from around 86.7 million cases in 2019...
The bladder cancer therapeutics market was valued at $670m in 2018 across the seven major markets (7MM*) and is expected to grow exponentially at a...
In the Northern Hemisphere, flu season is beginning in conjunction with the COVID-19 pandemic, however, influenza-like activity remains low in the US, with 40% fewer cases...
The number of diagnosed incident cases of acute lymphocytic leukemia (ALL) in the eight major markets (8MM*) is projected to increase from 23,729 in 2019...
Novartis recently registered a Phase III psoriatic arthritis (PsA) clinical trial of its IL-17 inhibitor Cosentyx (secukinumab) compared against Johnson & Johnson’s Stelara (ustekinumab). The...
The acute lymphocytic leukemia (ALL) market has enjoyed explosive growth since 2015 and is expected to increase further, albeit at a slower pace, from $1.46bn...
If the current trend in US COVID-19 cases continue, over 30% of the US population will have contracted the virus by July 2021, according...
China recorded the highest year-on-year increase in the number of clinical trials initiated investigating PD-1/PD-L1 targeted combination immuno-oncology therapies across the eight major markets (8MM*)...
A record number of late-breaking trials were submitted to the Annual Scientific Sessions of the American Heart Association (AHA) this year and unsurprisingly, a key...
The burden of diagnosed pancreatic ductal adenocarcinoma (PDAC) is expected to increase at an annual growth rate (AGR) of 2.60% from around 180,000 cases in...
Half of the companies in a ranking of top 20 global innovative pharmaceutical firms by data and analytics company GlobalData reported positive market capitalization (MCap)...
If Provention Bio’s rolling Biologic License Application (BLA) submission to the FDA for teplizumab is approved, teplizumab will be the first disease-modifying therapy for type...
Gmax Biopharm announced that the first patient has received its humanized monoclonal antibody drug, GMA301, as part of investigations around the drug’s efficacy for the...
The diagnosed prevalent cases of acromegaly in the seven major markets (7MM*) combined is projected to increase from 43,220 cases in 2019 to 47,340 in 2029,...
The idiopathic pulmonary fibrosis (IPF) market was valued at $2.5bn in 2019 across the seven major markets (7MM*), and is expected to grow to $3.6bn...
Following a controversial FDA Advisory Committee meeting for Biogen’s aducanumab for mild Alzheimer’s disease, where the panel members sharply recommended against approval, the therapy will...
Several pharmacological treatments for non-alcoholic steatohepatitis (NASH) are expected to be launched in the seven major markets (7MM*) over the next 10 years. It is...
Following the news that the Phase III study of the COVID-19 vaccine developed by Pfizer and BioNTech has been concluded and is showing 95% efficacy...
Akebia Therapeutics presented additional data from its Phase III PRO2TECT trial at the 2020 American Society of Nephrology Kidney Week conference, that evaluated the efficacy...
While Pfizer has witnessed a positive experience regarding the development of its Janus kinase (JAK) inhibitors, there is the distinct possibility that having so much...
Following Brainstorm Cell Therapeutics announcement of topline results for its anticipated amyotrophic lateral sclerosis (ALS) stem cell therapy NurOwn; Sarah Elsayed, Neurology Analyst at GlobalData, a...
Today (Wednesday 18 November) is World COPD Day 2020. Chronic obstructive pulmonary disease (COPD) is a group of respiratory diseases that hinder airflow cause breathing...
Marketed therapeutics for the treatment of acromegaly generated sales of at least $33m in Italy in 2019. The value of this market is expected to more than double, surpassing $75m in 2029, according to GlobalData, a leading data and analytics company. GlobalData’s recently published...
Vaccine developers are selecting contract manufacturing organizations (CMOs) close to home for their COVID-19 vaccine, as the US, UK and Germany are the most popular...
Several countries globally are now going through a second wave of COVID-19 infection. India is ranked second in terms of the confirmed COVID-19 cases globally....
Eli Lilly’s monoclonal antibody (mAb) bamlanivimab is unlikely to face payer pushback, despite its broad label, after recent FDA emergency use authorization (EUA) experts told...
COVID-19 is driving many small pharma companies that do not have the expertise or funds to run their own manufacturing facilities to outsource production. COVID-19...
The US Food and Drug Administration (FDA) recently announced the approval of Kala Pharmaceuticals’ Eysuvis, a topical steroid (0.25% loteprednol etabonate ophthalmic suspension), for short-term...
Following the news that Moderna has announced its COVID-19 vaccine, mRNA-1273, is 94.5% effective in first interim data readout; Michael Breen, PhD, Director of Infectious Diseases...
Type 2 diabetes (T2D) is a crowded and competitive landscape, with market growth primarily driven by an increasing diagnosed prevalent population across nine major markets...
Across the seven major markets* (7MM), the diagnosed prevalence of type 1 and 2 diabetes (T1D) was approximately 3.7 million and 49.7 million, respectively, in...
Following the publication of a review of Phase III clinical trials for drugs for schizophrenia by the FDA, which suggested improvements to clinical trial design; Philippa...
This year has been a record year for biotech initial public offerings (IPOs), with total deal value already up by 58% compared with all of...
Ardelyx and Kyowa’s tenapanor therapy for hyperphosphatemia (HP) in chronic kidney disease (CKD) patients who are on dialysis is likely to gain a front-line position...
Following the string of approvals this year for Roche's combination of Avastin (bevacizumab) and Tecentriq (atezolizumab), key opinion leaders interviewed by GlobalData from the five...
COVID-19 has been a wake-up call for pharma companies to rethink their operations and customer access. Embracing digital transformation will have an important role to...
With Pfizer and BioNTech announcing that a Phase III trial investigating the BNT162b2 vaccine to be 90% effective in preventing symptomatic COVID-19 in participants without...
In Japan, the breast cancer treatment landscape consists of various systemic therapies including chemotherapy, hormonal therapy, targeted therapy and immunotherapy. Key players in this space...
Ease of administration and dual protection of local and systemic immunity are promising drivers for intranasal vaccines’ adoption and compliance, particularly at a time when...
Following the news that Pfizer and BioNTech have announced their COVID-19 vaccine is more than 90% effective in first interim data readout; Philipp Rosenbaum, PhD, Senior...
Following the news that Pfizer and BioNTech have announced their COVID-19 vaccine is more than 90% effective in first interim data readout; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers...
A significant proportion of vaccine developers are smaller companies that lack the capacity and funds to manufacture their vaccines in-house. However, there is also simply not enough contract manufacturing capacity worldwide to cope with commercial COVID-19 vaccine demand,...
In response to the COVID-19 pandemic, Horizon 2020 (H2020), the EU’s biggest research and innovation program, invested almost €6M ($7.1M) for COVID-19 related research and drug development in...
COVID-19 is set to be a major catalyst for the pharmaceutical industry. The rush to adapt to new social distancing and lockdown norms has led...
One of the surprising notes around the interim results of the Phase II/III SOLIDARITY trial for COVID-19 is that remdesivir showed little to no effect....
Contract development and manufacturing organizations (CDMOs) are busier than ever, and their work will increase as the pandemic prompts pharma companies to increase redundancy in...
Following the release of FDA documents today noting support for the safety and efficacy of Biogen’s treatment for Alzheimer’s Disease (AD), aducanumab, it is looking...
The gastric and gastroesophageal adenocarcinoma (G/GEJAC) market is expected to grow from $1.6bn in 2019 to $3.9bn in 2029 across the eight major markets (8MM*)...
Fujifilm Diosynth Biotechnologies USA Inc., a contract development and manufacturing organization (CDMO), has shown a 200% increase in all deal volume for infectious disease drugs...
Trump and Biden have sharply contrasting policies on female patient accessibility to reproductive healthcare. Trump has repeatedly expressed his mandate to overturn the Affordable Care...
The number of diagnosed prevalent cases of Sjögren’s Syndrome (SS) in the seven major markets (7MM*) is projected to increase from 1.63 million in 2019 to...
Despite the high unmet needs within hepatocellular carcinoma (HCC), the market was stagnant from 2007 until 2018, when the FDA approved Eisai’s Lenvima (lenvatinib) in...
COVID-19 death rates in Poland have increased at an alarming pace since early April, from 4.7 deaths per million population to over 100, as of October 20....
Hyperimmune intravenous immunoglobulin (hIVIG), derived from plasma, could improve on efficacy of the Food and Drug Administration’s (FDA) authorized COVID-19 convalescent plasma treatment, but whether...
Following new data from Imperial College London (ICL) suggesting that antibody levels against SARS-CoV-2 wane over time; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology...
Telemedicine use in the US increased from the low ten thousands to around 1.3 million patients in 2020, representing more than 100-fold increase, according to...
The use of Emergency Use Authorizations (EUA) has been deeply polarizing in the US. With only days left until the presidential election, a growing number...
The current COVID-19 pandemic has caused the granting agency Innovate UK to prioritize innovative COVID-19 projects. Infectious disease has become the priority in terms of...
The contrast between US President Donald Trump and the Democrat nominee Joe Biden’s stances on healthcare are quite stark. While it is not immediately clear...
Dose contract manufacturing organizations (CMO) contract revenue in 2019 only grew 3.1% compared to 2018 revenue, which is one of the lowest rates since 2012,...
With the US’ Food and Drug Administration’s staging an all-day virtual meeting yesterday (22 October) regarding its planned standards for authorizing a COVID-19 vaccine; Reynald Castañeda,...
With over three-quarters* of US and European healthcare professionals saying they will continue using telemedicine after the COVID-19 crisis ends, governments are under pressure to...
Bristol-Myers Squibb’s (BMS) blockbuster combination of Opdivo and Yervoy is facing increasing scrutiny in various oncology indications as to whether the financial burden and clinical toxicity added by Yervoy is worth it. According to leading data and analytics company GlobalData, clinical trials with Opdivo monotherapy outnumber...
Following Amylyx’s announcement that AMX0035, its amyotrophic lateral sclerosis (ALS) pipeline drug, showed potential to prolong patient survival in addition to slowing rapid disease progression in the open label extension of Phase II/III clinical trial...
Following the news that the US and EU have blocked India's fight for intellectual property rights (IPR) waiver for COVID-19 drugs; Prashant Khadayate, Pharma Analyst at...
Reproductive health topics are perhaps some of the most divisive in US politics, with President Donald Trump, and his Democratic opponent, former Vice President Joe Biden, taking vastly different positions on several key issues in...
The launch of pentavalent vaccines from GlaxoSmithKline and Pfizer that protect against the meningococcal serogroups A, B, C, W, and Y (MenABCWY) in the nine...
The diagnosed prevalent cases of ulcerative colitis (UC) in the eight major markets (*8MM) are projected to increase from 1.7 million cases in 2019 to...
With recent pipeline approvals of varying mechanisms and an influx of newly diagnosed patients, the pulmonary arterial hypertension (PAH) market is expected to grow at...
Senior management of biopharma companies were more optimistic about the COVID-19 pandemic’s effect on imports/exports in Q3 compared to Q1, according to respondents who completed...
Following the news that the Indian state of Maharashtra has fixed the price of remdesivir; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics...
Pharma companies across the globe are working to develop a vaccine against COVID-19, which has already infected more than 38 million globally. Against this backdrop,...
Diagnosed prevalent cases of diabetic retinopathy in the nine major markets (9MM*) are expected to increase from 14.3 million in 2019 to 17.8 million in 2029, at...
The Crohn’s disease (CD) market is expected to grow from $7.4bn in 2019 to $12.6bn by 2029 across the eight major markets (8MM*) at a...
New data unveiled at the United European Gastroenterology Week (UEGW) virtual conference showed that Eli Lilly’s Crohn’s disease (CD) hopeful, mirikizumab, can deliver durable endoscopic and symptomatic efficacy...
Second waves of COVID-19 worldwide will coincide with the start of the winter months in the northern hemisphere and with the flu season, making the...
Following reports that COVID-19 may cause lingering heart damage; Vinie Varkey, M.Sc, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view:...
Following the announcement of positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory...
October is Breast Cancer Awareness Month, a worldwide annual campaign that highlights the importance of breast cancer awareness, education and research. One of the consequences of...
The total number of trials disrupted by COVID-19 since June has been falling slowly, while trials impacted by slow enrollment continue to increase. For trials...
The daily confirmed cases of COVID-19 in France is increasing, which could indicate that the country is experiencing a second wave of COVID-19. The spike...
Czechia is experiencing a spike in daily confirmed cases of COVID-19, indicating the onset of a second wave. However, despite the increase in new cases,...
The COVID-19 pandemic created an unprecedented demand for digital solutions for the delivery of safe and effective mental health treatment such as telemedicine. Even now,...
As US President Donald J. Trump puts his weight behind Eli Lilly and Regeneron Pharmaceuticals’ bid for an FDA Emergency Use Authorization (EUA) for their...
Pfizer’s recent investment of $200m in China’s CStone Pharmaceuticals for the development of a second-generation immuno-oncology agent is the latest partnership between US and Chinese...
Should the latest guidelines proposal by the US Preventive Services Task Force (USPSTF) for the screening of lung cancer take effect, GlobalData epidemiologists predict that...
Following the news that Axovant announced positive six-month follow-up data from its Phase II trial of AXO-Lenti-PD for the treatment of Parkinson’s Disease (PD); Philippa Salter,...
There is an M&A opportunity for large contract manufacturing organizations (CMOs) in North America and Europe to acquire facilities able to produce medicines with lower...
Clinical trials disrupted by COVID-19 are expected to resume at a much slower rate than originally anticipated, as more nations are re-enforcing lockdown due to...
With the European Medicines Agency (EMA) announcing today that it will also initiate a rolling review of the COVID-19 vaccine developed by Pfizer and BioNTech...
Acceleron Pharma’s sotatercept, was granted priority designation by the European Medicines Agency for pulmonary arterial hypertension (PAH) in May 2020. This further signifies the drug’s...
The FDA has removed a boxed warning concerning the risk of leg and foot amputations for Janssen’s sodium glucose co-transporter (SGLT) inhibitor, Invokana (canagliflozin) -...
Senior management of biopharma companies across North America, Europe and the Asia Pacific (APAC) region were more optimistic about the COVID-19 pandemic’s impact on annual...
Many surgical procedures have been postponed during 2020 due to COVID-19. This will lead to over 11% loss of revenue from urinary tract stents in...
Gaining approval by the EC and Japanese Ministry of Health, Labour and Welfare (MHLW) on the same day for adults with moderate-to-severe active rheumatoid arthritis...
Bausch Health recently announced that it had entered into an agreement with Allegro to acquire an option to purchase all of the latter’s ophthalmology assets....
Oral GnRH antagonists have off-label potential in the female infertility space, beyond the indications of endometriosis-associated pain and uterine fibroids, which constitute the main development...
Three-fourths of dose manufacturing facilities acquired by dedicated CMOs in 2019 were located in Europe, according to an analysis of sites supplying the US, Canada,...
The pharma manufacturing in the three Southern Indian states of Karnataka, Tamil Nadu and Kerala, and Goa (Western India) has a high merger and acquisition...
Pharma companies around the world are exploring innovative approaches to develop therapeutics and vaccines against COVID-19. One of these innovations is using a nasal spray...
Following President Trump’s announced executive order directing the Department of Health and Human Services (HHS) to issue rules ensuring that specific regulatory changes to telemedicine...
Following the news that Roche has announced new positive two-year data for Evrysdi (risdiplam) in infants with spinal muscular atrophy (SMA); Philippa Salter, Neurology Analyst at...
Following the news that Roche has announced new positive two-year data for Evrysdi (risdiplam) in infants with spinal muscular atrophy (SMA); Philippa Salter, Neurology Analyst at...
The late-stage ALS pipeline has several promising therapies that look to address some of the unmet needs in the market. Pipeline strategies have focused on...
The clinical success of Amgen’s Blincyto has amplified the intensive pace of development for bispecific antibodies in oncology. According to GlobalData’s drugs database, there are...
In light of another setback in the Alzheimer’s disease (AD) drug development field, with the failure of Roche and AC Immune’s antitau antibody, all eyes...
The diagnosed prevalent cases of Crohn’s disease (CD) in the eight major markets (*8MM) are projected to increase from 1,339,543 cases in 2019 to 1,629,940 cases...
Following a review of data from the Phase I STRONG study of the intrathecal (IT) formulation of Novartis’ one-off gene therapy Zolgensma (onasemnogene abeparvovec) in...
The diagnosed prevalent cases of pulmonary arterial hypertension (PAH) in the seven major markets (*7MM) is expected to increase from 67,400 cases in 2019 to...
The diagnosed prevalent cases of amyotrophic lateral sclerosis (ALS) in the eight major markets (*8MM) is expected to increase from 57,800 cases in 2019 to...
The opioid use disorder (OUD) market is expected to grow from $1.6bn in 2018 to $3.7bn by 2028 across the eight major markets (8MM*) at...
Eli Lilly’s baricitinib, marketed as Olumiant in rheumatoid arthritis, has received a recommendation of approval from the European Medicines Agency’s (EMA) Committee for Medicinal Products...
Several COVID-19 outbreaks across the US since mid-June have been traced back to bars and nightclubs as the source of contagion. This coincides with a...
One of the most worrying issues in regard to US healthcare is that the cost of treatment and therapeutics is unreasonably high - often to...
World Alzheimer’s Day 2020 (21 September) serves as a timely reminder that drug development in this space is slow, as the Alzheimer’s disease (AD) drug...
A second spike of cases was seen in the UK at the start of August, and while the new daily cases are currently increasing at...
Following the news that India-based Dr. Reddy’s Laboratories (Dr Reddy’s) has partnered with the Russian Direct Investment Fund (RDIF) to distribute the COVID-19 vaccine Sputnik...
Eli Lilly and Boehringer Ingelheim’s (BI’s) Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) are expected to drive heart failure (HF) market growth and achieve high uptake...
Alkermes’ schizophrenia/bipolar disorder candidate ALKS-3831 weight gain data will be at the forefront of a 9 October FDA Advisory Committee (AdCom) meeting, but how the panel members will evaluate it is up for debate, as reported...
At least 99 publicly owned pharma companies and contract manufacturing organizations (CMOs) – many with substantial market value and access to capital markets – were approved to receive PPP loans that were intended to help small businesses in...
Following the publication of new positive data from the Phase IIIb CASTING trial of Roche’s Ocrevus (ocrelizumab) in patients with relapsing-remitting multiple sclerosis (RRMS); Alessio Brunello,...
Phase IIb results were published in July for Shield Therapeutics’ oral iron-based phosphate binder PT20 for the treatment of hyperphosphatemia (HPT) in dialysis-dependent chronic kidney...
Amarin Corporation recently presented final results from the EVAPORATE trial in which Vascepa (icosapent ethyl) reduced patients’ coronary plaque by 17% compared to placebo following...
Many pharmaceutical companies have performed well, despite the impact of COVID-19, as all of the top 20 global innovative bio/pharma companies, ranked by market capitalization...
The US biosimilar drugs market has failed to deliver on the promise of making biologics more affordable and widespread. The education of all sectors of...
In Japan, the treatment landscape for inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is mature and encompassing many conventional therapies...
Inovio was one of the first of the over 200 companies to enter the pre-clinical development of a prophylactic COVID-19 vaccine (INO-4800), but the progress...
A total 73% of cardiology, gastroenterology, pulmonology, and respiratory specialists in the US, Europe, the UK and Japan indicated that their use of telemedicine has...
The diabetic retinopathy (DR) market has been dominated by neovascularization inhibitors, and this group of therapies is expected to generate more than $6.8bn in sales...
As more than 7,000 cell and gene therapies progress through the development pipeline and only 152 CMOs have the capabilities to manufacture them, production bottlenecks...
The COVID-19 induced lockdown resulted in an unprecedented rise in e-commerce transactions across India. In line with this, e-pharma sector also witnessed growth despite regulatory...
While the COVID-19 pandemic continues to cause high numbers of confirmed new cases in Brazil, the patient population available for the increasing number of COVID-19...
Sanofi’s progress in research and development (R&D) has been adversely impacted by the COVID-19 pandemic. As of late August, six of Sanofi’s clinical trials, which...
A total of 198 small- and mid-cap Bio/Pharma companies are currently involved in vaccine or therapeutic development for COVID-19, with a total of 244 unique...
Gene therapies dominate the pipeline landscape for retinitis pigmentosa (RP) with the gene coding for retinitis pigmentosa GTPase regulator (RPGR) the most common target among these...
Following the news that Type 2 diabetes sufferers in the UK were put on a soup and shake diet by the NHS; Akash Patel, Cardiovascular &...
If AbbVie is successful with its FDA application submission for JAK inhibitor Rinvoq in adult patients with ankylosing spondylitis (AS), the drug is expected to...
Healthcare experts have noted that their number one primary concern amid the COVID-19 pandemic was the delay to initiation or inability to conduct clinical trials,...
Reimbursement for dialysis patients on AstraZeneca’s/FibroGen’s roxadustat needs to be untangled such that it can be billed separately and be accompanied by hikes in eventual...
More than 1,200 therapeutics and vaccines have entered the research and development (R&D) pipeline since January 2020, according to GlobalData, a leading data and analytics...
Following the news that the FDA granted an EUA for convalescent plasma as a treatment option for COVID-19; Angad Lotay MPharm, Infectious Diseases Analyst at GlobalData,...
India is overhauling its pharma regulatory norms to expedite approval process and promote innovation. Given that the country is now focused more than ever on...
Following the news that Takeda and Ovid’s epilepsy drug soticlestat achieved positive Phase II trial results in children with hard-to-treat epilepsy syndromes; Philippa Salter, Neurology Analyst...
In a recent GlobalData poll* 38% felt that mRNA COVID-19 vaccines are the most promising of the vaccine technologies, noticeably beating DNA vaccines, which only...
The digital hospital-to-pharmacy referral scheme is taking time to materialize despite the significant benefits it would provide to the UK. With adverse drug events being...
The market for graft versus host disease (GvHD) prophylaxis and treatment in the five growth markets (5GM*) in the Asia-Pacific (APAC) region will undergo steady...
Use of telemedicine by US physicians has increased significantly as a result of the COVID-19 outbreak. In a survey conducted by data and analytics company...
Japan is now experiencing a second wave that is much larger than the first after having COVID-19 under control for over a month. The country...
Trilaciclib’s new drug application (NDA) acceptance signals a significant moment for cancer patients that need support with chemotherapy-induced toxicities - further highlighted by the fact...
Hepatocellular carcinoma (HCC) treatment has been deferred due to overburdened healthcare systems as a result of the COVID-19 pandemic. Leading data and analytics company GlobalData...
In a global prescription drug market worth over $600bn, oncology has become the dominant area, claiming a market share of 23.4% as of 2019, followed...
At present, more than 200 prophylactic vaccines are in development for COVID-19. While promising candidates should be selected for diversity, the novel nature of SARS-CoV-2...
Biotech company initial public offering (IPO) valuations have shown resilience during the COVID-19 pandemic, compared to other industries. This is largely due to the unique...
Global pharmaceutical industry job postings see recovery in Q3 thus far, following a decline in Q2 2020 Takeda’s workforce size of 49,578 as of...
In a recent GlobalData poll*, healthcare experts estimated that it would take some time for the clinical trials that were disrupted due to COVID-19 to...
In light of AstraZeneca’s denial that is it speaking to the FDA to push an emergency use authorisation for its COVID-19 vaccine, AZD1222; Reynald Castañeda, Pharma...
Telemedicine looks to be here to stay as leading companies in this space have reported dramatic increases in demand for their services in the US...
Following the recent news that BioMarin received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) indicating that its gene therapy for severe hemophilia A, ValRox (valoctocogene roxaparvovec), was not yet ready for approval; Tajekesa Chapman, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers...
COVID-19 cases began increasing in Spain from July, which, while could be partially down to an increase in COVID-19 testing, does coincide with the holiday...
Aimmune’s Palforzia (peanut allergy powder) has seen a slower uptake due to a knock-on effect of the COVID-19 pandemic. Uptake of new drugs such as...
Gilead received a big shock following the FDA’s complete response letter (CRL) for filgotinib. While there has always been concerns surrounding the Janus kinase (JAK)...
The use of stem cells to “re-awaken” the ovaries in women with premature ovarian failure (POF) pave the way for novel treatments for this cause of infertility, says GlobalData, a leading data and analytics company. Despite their young age, POF patients face...
Following the news that UK Health Secretary Matt Hancock has announced National Institution for Health Protection; Michael Breen, Director of Infectious Diseases at GlobalData, offers his...
Adcetris is the market-leading drug in the world’s 7MM* (US, 5EU and Japan) and the main contributor to the market growth in Hodgkin’s lymphoma (HL)...
India’s contract manufacturing organization (CMO) and pharma market has strongly attracted investment from global private equity firms in recent times, driven by favorable government policies...
At present, 37.8% of oncology trials that were disrupted by COVID-19 have resumed, according to GlobalData, a leading data and analytics company. This marks the...
The UK has one of the highest flu vaccination rates in the world. However, the COVID-19 pandemic is increasing appointment times due to extra precautions...
The number of total disrupted clinical trials has begun to fall since June, however, only trials that suspended enrollment have been on a downward trajectory,...
Opdivo is set to become the market leader in gastric in gastro-oesophageal cancer following the latest data from two label expansion trials, which were noted...
India is making rapid progress in the development of indigenous COVID-19 vaccines. With increase in the number of COVID-19 positive cases, their success will make...
Following the news that Russia has approved the first COVID-19 vaccine; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company,...
Following the news of Eli Lilly and Company initiating a Phase III trial for their monoclonal antibody, LY-CoV555, for the prevention of COVID-19 in nursing...
Recent study findings from the US Centers for Disease Control and Prevention (CDC) suggest there may be a difference in disease severity when comparing pregnant...
AstraZeneca’s Farxiga (dapagliflozin) is expected to significantly strengthen its presence in the the sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class of the cardiovascular and metabolic arena after...
Following the FDA’s recently granted accelerated approval for Morphosys and Incyte’s CD19 targeting antibody Monjuvi (tafasitamab), Morphosys and Incyte partnership now pushes forward to compete...
Licensing agreements are decreasing in the rare disease space in favor of more complex collaborations and partnerships. Indeed, of the strategic alliances formed by the...
With the rapid proliferation of clinical trials addressing COVID-19, the US National Institutes of Health (NIH) launched the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)...
As another great year for the innovation bio/pharma industry, 2019 saw 17 of the top 20 mega cap players reporting YoY revenue growth, according to...
Following the news that the first subcutaneous (SC) formulation of Celltrion’s Remsima (infliximab-dyyb/CT-P13) was granted marketing authorization by the European Commission (EC) for all indications...
Since early May, there has been a second surge of the COVID-19 pandemic in Iran. In comparison to other countries, the number of daily deaths...
Following the publication of positive top-line data from the Phase II EMPhASIS trial of IMU-838 (vidofludimus calcium) in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) by...
Following the news that there is evidence that COVID-19 infection in pregnant women can exhibit signs that mimic a severe form of preeclampsia such as...
Regulatory bodies such as the National Pharmaceutical Pricing Authority (NPPA) and the Drug Controller General of India (DCGI) are keeping a close eye on remdesivir...
The US is seeing a steep rise in the number of new cases each day. The failure of the country to adopt a widespread use...
Novaliq recently announced its agreement with the US Food and Drug Administration (FDA) regarding the second registrational trial ESSENCE-2 for its late-stage therapy, CyclASol, for...
Biocon Sdn. Bhd., Malaysia, a subsidiary of Biocon Biologics, and digital therapeutics company Voluntis have recently announced a global collaboration agreement to develop and distribute...
Following the news that the Food and Drug Administration granted AstraZeneca’s Breztri approval in the US for chronic obstructive pulmonary disease (COPD); Angad Lotay, MPharm, Pharma...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from oncology influencers increased significantly, with content peaking in...
Nearly half of all 12-month total prevalent cases of opioid use disorder (OUD) occur in the population ages 18–39 years, followed by the age group...
The costs of treatment and the impact that the COVID-19 pandemic is having on the healthcare system remains a concern, says GlobalData, a leading data...
Although AstraZeneca, Johnson & Johnson/AbbVie and BeiGene all have oncology therapies, known as BTK inhibitors, repurposed for COVID-19 treatment, there are still important nuanced differences,...
Nearly half of global respondents to a poll by GlobalData believe that those in high-risk groups such as the elderly and patients with co-morbidities, should...
Liquidia Technologies’ planned acquisition of RareGen in Q4 will be a significant opportunity for Liquidia to expand its rare diseases pipeline, bolster its pulmonary arterial...
There are more than 1,039 COVID-19 potential drugs and 2,737 clinical trials for COVID-19 globally, with more than 430 of these being run in the...
Findings from Phase II trials of Clinigen’s Proleukin (aldesleukin) have suggested an overall shift toward immunosuppression in amyotrophic lateral sclerosis (ALS) patients who were given...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from infectious diseases influencers increased significantly, with content peaking...
Infectious disease drugs have overtaken oncology as the year’s top therapy area for contract service agreements (CSAs) as companies are shifting their current focus to...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from metabolic disorders influencers increased significantly, with content peaking...
Following today’s news (Thursday 23 July) that Incyte’s Jakafi (ruxolitinib) met its primary endpoint in its Phase III REACH-3 chronic graft-versus-host-disease (GvHD) study; James Mather, MChem,...
Based on the current trajectory of COVID-19 daily confirmed cases, South Africa is among the most heavily affected countries in the world, with a forecast of...
The transthyretin amyloidosis (ATTR) market is expected to grow from $585m in 2019 to $14.1bn in 2029 across the seven major markets (7MM*) at an...
Following Synairgen’s positive interim results from its inhaled interferon beta therapy, SNG001; Johanna Swanson, Product Manager at GlobalData, a leading data and analytics company, offers her...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to COVID-19 from cardiovascular influencers increased significantly, with content peaking in April,...
Following the news that Biogen is planning a Phase IV trial to test Spinraza (nusinersen) in patients with spinal muscular atrophy (SMA) who have already...
Australia’s initial response to the novel coronavirus was among the most successful worldwide. However, a recent increase in daily confirmed cases since the start of...
Following the news that interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune...
Following the news that AstraZeneca and Oxford University published Phase I/II results of their COVID-19 vaccine candidate ChAdOx1/AZD1222; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst and...
Following the news that Chinese biotech CanSino published Phase II results of its COVID-19 vaccine candidate Ad5-nCoV; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData,...
Following the news that UK biotech Synairgen announced reductions in COVID-19 disease progression and increased rates of recovery relative to placebo; Michael Breen, PhD, Director of...
Following the recent launch of Covifor (remdesivir) by Hetero in India, remdesivir has emerged as the most sought-after drug for the treatment of moderate to...
As countries begin to reopen from COVID-19, one of the currently important issues to examine is that of school re-openings. As infected children generally have...
The COVID-19 pandemic has caused some disruptions in Contract Manufacturing Service Agreements (CSAs), says GlobalData, a leading data and analytics company. Johanna Swanson, Product Manager at...
China is among the leading countries that are aggressively involved in developing vaccines for COVID-19, with one vaccine each from Sinopharm Group and Sinovac Biotech...
Janssen, a subsidiary of Johnson and Johnson (J&J), recently announced that Tremfya (guselkumab) received Food and Drug Administration (FDA) approval for patients with active psoriatic...
As the COVID-19 pandemic continues to disrupt companies, some have come out as winners or losers. Developers with COVID-19 therapies and vaccines will benefit in...
Following the recent news that the US Department of Health and Human Services (HHS) will be receiving data on COVID-19 hospitalizations from hospitals directly, bypassing...
Following the results of a Phase IIb/III trial that showed GSK’s investigational HIV prevention drug cabotegravir had superior efficacy over Gilead’s Truvada; Arafa Salam, PhD, Infectious...
Following the promising results from Moderna’s mRNA vaccine Phase I trial; Johanna Swanson, Product Manager at GlobalData, a leading data and analytics company, offers her view: “The...
As a vaccine product passes through clinical development, manufacturers will have to ensure that they are taking the required steps to ramp up production, as...
There are indications that some companies may be expediting the approval of COVID-19 vaccines, sometimes with subpar effectiveness, in response to pressure from governmental organizations....
The northern Chinese province of Hebei offers great potential for pharmaceutical investment as it has been one of the leading regions for pharmaceutical production. Though...
COVID-19 research and development (R&D) has started to see the first set of novel drug candidates enter clinical trials by way of monoclonal antibodies (mAbs)....
Strict lockdown measures in Peru have done little to curb the spread of COVID-19. GlobalData’s forecast for Peru indicates that the country may have reached...
Following the news that India-based biopharma company Biocon’s plaque psoriasis drug itolizumab (ALZUMAb) has secured approval from the Drugs Controller General of India (DCGI) for...
Following the FDA’s approval of Hulio (adalimumab-fkjp), a biosimilar of AbbVie’s Humira that was the highest grossing drug for eight years running with $19.2bn in...
Despite recent advances in idiopathic pulmonary fibrosis (IPF), significant unmet needs remain including increased earlier diagnosis, improved drug safety and efficacy, improvement in patient quality...
COVID-19 has had a catalytic effect on emerging technologies and has pushed several technologies into the forefront of methods to manage the pandemic. This is likely to be a watershed event and...
Pharma manufacturing is exempted from the lockdown measures in India; however, the movement of materials appears still to be limited, the workforce to carry out...
After three months of increasing trial disruptions, the number of disrupted trials began to fall between June and July. Most disruption was caused by the...
The US Federal Government’s Biomedical Advanced Research and Development Authority (BARDA) award of $354m to Phlow Corporation for the manufacture of COVID-19 medicines and other...
South Korea-based bio/pharma company Celltrion has recently agreed to acquire a portfolio of 18 prescription pharmaceutical products and over-the-counter medicines across the Asia-Pacific (APAC) region...
India-based Cipla has recently entered into a partnership with Boehringer Ingelheim (BI) India Pvt. Ltd. to co-market three new oral anti-diabetics drugs in India, mainly...
The Hodgkin’s lymphoma (HL) market is expected to grow from $1.2bn in 2019 to $2.1bn in 2029 across the eight major markets (8MM*) at a...
Following Biogen’s submission of a Biologics License Application (BLA) to the FDA of aducanumab; Alessio Brunello, Managing Pharma Analyst at GlobalData, a leading data and analytics...
Following the news that US biotech Novavax announced it will receive $1.6bn funding for the development of its COVID-19 vaccine candidate NVX-CoV2373; Philipp Rosenbaum, PhD, Senior...
The number of diagnosed prevalent cases of AL amyloidosis is expected to increase from 75,033 in 2019 to 89,637 in 2029 at an annual growth...
The burden of diagnosed Hodgkin lymphoma (HL) is expected to increase at an annual growth rate (AGR) of 0.90% from around 25,000 cases in 2019...
Following the news that Indian pharmaceutical giant Dr. Reddy’s Laboratories (Dr Reddy’s) has signed tripartite agreement with Tokyo-based FUJIFILM Toyama Chemical and Dubai-based Global Response...
Long-term complications arising in COVID-19 patients after recovering from the initial illness are expected to increase healthcare costs in the long-term. Complications such as stroke,...
In the seven major pharmaceutical markets (7MM*), less than half of non-alcoholic steatohepatitis (NASH) cases were diagnosed in 2019, says GlobalData, a leading data and...
Following Bristol Myers Squibb’s positive topline results from its pivotal Phase III TRUE NORTH trial, it is possible that oral sphingosine1‐phosphate (S1P) Zeposia could have...
As the world continues to brace for a COVID-19 triggered economic downturn and with the Brexit transition period extension deadline ending on 30 June; Urte Jakimaviciute,...
Following the news that the US secured virtually all available short-term stock of remdesivir; Brian Hicks, Medical Devices Analyst at GlobalData, a leading data and analytics...
Following the US FDA’s issuance of its guidance document; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “The US Food and...
The COVID-19 pandemic has led to temporarily increased drug sales for biggest bio/pharma companies in the first quarter (Q1) of 2020. This increase over sales...
COVID-19 could be causing patients with Hodgkin lymphoma and other cancers to delay seeking care, which in turn could delay those patients from receiving a...
Since early March, over a hundred companies have publicly announced disruptions to planned and ongoing clinical trials in their press releases, SEC filings, as well...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from neurology influencers increased significantly, with content peaking in...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from immunology influencers increased significantly, with content peaking in...
The number of social media posts made by digital pharma influencers related to COVID-19 has increased significantly since it was declared a pandemic in March,...
In the UK and US, there is a pattern of minority ethnic groups having a higher risk of death due to COVID-19 compared with their...
The usefulness of adenovirus-vectored vaccines for COVID-19 is currently questionable as these should only be administered two times over the lifetime of an individual and...
The short duration of the COVID-19 antibodies throws into doubt the concept of immunity passports for this illness, as those who caught the disease could potentially catch it again. This is...
A total *76% of people, as surveyed by GlobalData, expect telemedicine to be used widely once the pandemic had abated. Kathryn Whitney, MSc, Director of Thematic...
At the beginning of June, more than 70% of trials were being run by non-industry sponsors, and the majority of clinical trial sponsors were based...
There are concerns over the pricing of remdesivir and how to make it available in low-income and lower-middle income countries, says GlobalData, a leading data...
Novo Nordisk’s recent announcement of positive topline data from its Phase IIIa study STEP 4, investigating the use of semaglutide to treat obesity, will enable...
The myelodysplastic syndromes (MDS) market is expected to grow from $1.6bn in 2018 to $2.4bn in 2028 across the seven major markets (7MM*) at a...
Following the FDA approval of Ferring Pharmaceuticals’ once-weekly progesterone vaginal ring for luteal phase support in women undergoing assisted reproductive technology (ART) treatment cycles, the...
The health and fitness wearables that monitor physiological parameters such as heart rate, body temperature, sleeping patterns, blood pressure and oxygen saturation levels may become...
Tonix Pharmaceuticals and Southern Research have partnered to create a COVID-19 vaccine based on Tonix’s proprietary horsepox vaccine platform. The use of the horsepox vector...
While researchers investigate recovered patient antibody treatments for COVID-19, intravenous immunoglobulin (IVIg) is a similar type of treatment that is already available and could be...
After receiving a world-first approval by the UK Government, following groundbreaking data showing it can reduce COVID-19 deaths among hospitalized patients, the inexpensive and widely...
Following Gilead’s announcement that it will begin Phase I clinical trials for inhaled remdesivir in healthy volunteers, data and analytics company GlobalData anticipates that a...
Acute myeloid leukemia (AML), a serious haematological cancer, remains a disease often defined by poor prognosis. However, less than 30% of diagnosed incident cases of...
Despite the COVID-19 challenges, most of the big bio/pharma companies had reported temporary increase in drug sales in Q1 2020, mainly due to the stockpiling...
Drug sales for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) collectively reached $2.2bn in 2018 across the eight major markets (8MM*). By the end...
Following the news that Indian drug firms cheer dexamethasone’s efficacy in severe COVID-19 patients;Nag Madhavi, Pharma Analyst at GlobalData, a leading data and analytics company,...
Following the news that domestic pharma giants Cipla and Hetero have received the Drugs Controller General of India’s (DGCI) approval to launch generic versions of...
The launch of new therapies between 2018 and 2028, including new classes of drugs with novel mechanisms of action (MOAs), and an anticipated increase in...
The phase distribution of clinical trials in Europe suggests that sponsors are focusing primarily on repurposing available therapies to treat COVID-19 and that the level...
Following the news that Glenmark Pharmaceuticals has become the first company in India to receive regulatory approval for oral antiviral favipiravir for the treatment of...
The effects of the COVID-19 pandemic on the market capitalization (market cap) of companies are mitigated by having a COVID-19 drug in their pipeline, with...
As the COVID-19 pandemic continues to sweep across the US, around 12% of intensive care hospitalized COVID-19 patients need to be placed on a ventilator. Not...
BeiGene has recently received approval for its second-generation Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) from the China National Medical Products Administration (NMPA). The China-based...
COVID-19 deaths are most likely being underreported in the US, according to GlobalData, a leading data and analytics company. Excess deaths measure the difference between observed...
The burden of diagnosed myelodysplastic syndrome (MDS) is expected to increase at an annual growth rate (AGR) of 2.40% from around 90,000 cases in 2018...
Comorbidity is a major concern in people with angina pectoris as, in 2019, there were nearly 20 million diagnosed prevalent cases of angina pectoris in...
Countries are beginning to reopen due to economic and social pressures, while keeping an eye on the threat of resurgences. Based on trends observed in...
In order to achieve ‘herd immunity’ to COVID-19, there are estimates that anywhere from 50–90% of the population will need to achieve immunity. This will...
The adoption of telemedicine has been accelerated significantly in the wake of COVID-19 outbreak. However, despite the increasing usage of the telehealth solutions, this innovation...
The COVID-19 pandemic presents significant growth opportunities for mental health and wellbeing technologies, however, telemedicine cannot replace in-person visits and these innovations will not resolve...
Clinical trial results for Gilead Science’s remdesivir have shown modest improvement in the recovery of moderately ill COVID-19 patients and remdesivir’s success in humans could...
The acute myeloid leukemia (AML) market is expected to grow from $1.4bn in 2019 to $5.1bn in 2029 across the eight major markets (8MM*) at...
Having a COVID-19 drug in a bio/pharma company’s pipeline resulted in a smaller decrease in market capitalization (market cap) during the first quarter (Q1) of...
The International Alliance of Amyotrophic Lateral Sclerosis (ALS)/ Motor Neuron Disease (MND) Associations, recognizes June 21 as the ALS Global Day. The goal of this...
Some children have developed a severe inflammatory response due to COVID-19 infection that appears similar to Kawasaki disease. Doctors are referring to this response as...
Despite receiving Food and Drug Administration (FDA) approval for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) before Novartis’s Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) will...
Serum Institute of India (SII) is the world’s largest vaccine producer in terms of volume. SII is currently working on three candidates for COVID-19, including...
The pharma sector saw promising year-on-year (YoY) growth in 2019, compared to the previous year, with 16 of the top 20 companies by market capitalization...
Oral selexipag could improve treatment for the pediatric population based on its convenient administration, better safety and better tolerability profile compared to currently available options...
Hydroxychloroquine may have resulted in a large amount of wasted effort towards finding a treatment for COVID-19 as another hydroxychloroquine study has shown no benefits...
The clean energy sector had been one of the biggest and fastest-growing sectors in the US since 2015, having employed over 3 million people. However,...
As the COVID-19 pandemic continues to evolve across the globe, a large amount of data on its epidemiology has been generated. Finding relationships and predictive...
Latin American countries are showing dangerous trends of increasing COVID-19 cases. Brazil, Peru, Chile, and Mexico are now ranked second, tenth, thirteenth, and fourteenth, respectively,...
More than 200 trials that were previously disrupted from the COVID-19 pandemic by delayed initiation and slow or suspended enrollment are now ongoing or completed....
The global COVID-19 pandemic has become a catalyst for the pharma industry and the US Food and Drug Administration (FDA) to implement long-awaited innovations. The...
Following the publication of a new study of the long-term effectiveness of midomafetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD);Philippa Salter, Neurology Analyst...
Following today’s news (Monday 15 June) that the FDA has pulled emergency use authorization of hydroxychloroquine for COVID-19;Johanna Swanson, Product Manager at GlobalData, a leading...
Gilead is likely preparing for remdesivir’s approval and launch, based on an analysis of GlobalData’s Job Analytics database. As an operational reaction to the COVID-19...
Moderna’s mRNA-1273 vaccine for COVID-19 is currently in Phase I development and is targeted for an aggressive commercial launch in 2021. The vaccine candidate’s peak...
The COVID-19 pandemic has exposed weaknesses around the US healthcare system and resulted in a large amount of uncertainty around the healthcare and health insurance...
Following the news that the Indian state of Maharashtra is planning to procure Gilead Sciences' antiviral drug remdesivir from Bangladesh-based pharmaceutical giant Eskayef Pharmaceuticals; Anupama...
Moderna Therapeutics recently received Fast-Track designation from the FDA for its COVID-19 candidate vaccine, mRNA-1273 together with the green light to initiate a Phase II clinical...
After a little over 100 days since the first confirmed case of COVID-19 reported on 28 February 2020, New Zealand has lifted almost all restrictions...
COVID-19 presents a challenge to physicians managing patients with multiple sclerosis (MS), due to concerns about using immunotherapies to treat this neurological condition, in the...
A recent research study showed that for 16 COVID19 positive women there were evidences that their placentas had blood clots and indications of abnormal blood...
Bayer donated millions of tablets of chloroquine to national health authorities around the world in anticipation of its possible usage as a treatment for COVID-19....
While Gilead Sciences’ remdesivir has been declared the new standard of care for COVID-19 despite some mixed trial results, it will continue to face challenges...
Recently, Brazil has steadily climbed the chart of the top 10 countries with the highest total of COVID19 cases, now ranking number two just behind...
If the development of Liquidia Technologies’ LIQ-861 dry powder inhaled formulation of treprostinil, indicated for the treatment of pulmonary arterial hypertension (PAH) is successful, the...
There is no clinical evidence that hydroxychloroquine is effective against COVID19. Some studies using hydroxychloroquine have shown no benefits or even an increase in risk...
As of mid-May, there were 131 contract manufacturing organizations (CMOs) in Spain with 161 Spanish sites, according to the GlobalData’s Contract Service Provider database, which...
A large number of COVID-19 treatment options (620 novel and repurposed drugs as of mid-May) have joined the drug development pipeline, with over 72% of...
The news that at least five publicly traded contract manufacturing organizations (CMOs) took out Paycheck Protection Program (PPP) loans from the US Government’s $659bn loan...
Oyster Point announced that top-line results from its Phase III Onset-2 trial evaluating OC-01 for dry eye disease (DES) in early May. The results demonstrated...
COVID-19–accelerated adoption of emerging technologies will revolutionize the frontline staff education and training process and become a new normal once the COVID-19 crisis ends, says...
GlobalData anticipates that Gilead’s remdesivir will target a select severity group of COVID-19 patients, and it remains questionable as to how treatment with the drug...
When clinical trials that were delayed since the beginning of the COVID-19 pandemic resume, it is highly probable that potential trial subjects will have a...
Based on the current trajectory of COVID19 daily confirmed cases, India will be the fourth most heavily affected country in the world behind the US,...
The COVID-19 pandemic has been disrupting clinical trials globally, but as countries reopen, these trials are now resuming. As of 28th May, over 130 COVID-19 disrupted...
The spread of the COVID-19 can be slowed by the use of interferon-lambda, which has the ability to inhibit replication of COVID-19 in the lungs...
A recent Phase I clinical trial performed at the University Medical Center Hamburg-Eppendorf for a Middle East respiratory syndrome (MERS) vaccine has produced positive results...
Following the news that the US Government’s ‘Operation Warp Speed’ picked AstraZeneca, Johnson & Johnson, Merck, Moderna, and Pfizer as finalists for COVID-19 vaccine funding; Philipp...
Nearly 60% of all diagnosed prevalent cases of dry eye syndrome (DES) occur in women. Women who are pregnant, on certain types of birth control,...
Remicade (infliximab) and Humira (adalimumab) are the established anti-tumor necrosis factor (TNF) therapies that have been shown to decrease inflammation in diseases such as rheumatoid arthritis (RA) and...
Even though blockchain stands out as a potential solution to improve pharmaceutical supply chains, COVID-19 may become a hindrance rather than a trigger in the...
The ongoing COVID-19 pandemic has increased the demand for drugs used to sedate the mechanically ventilated COVID-19 patients and has resulted in shortages for some of these...
Following the review extension from the Food and Drug Administration (FDA) of anti-CD20 monoclonal antibody drugs for multiple sclerosis (MS) to September 2020, which will...
The local production of the active pharmaceutical ingredients (API) for some of the key COVID-19 repurposed drugs including remdesivir, favipiravir and hydroxychloroquine (HCQ) is likely to offer a...
Paycheck Protection Program (PPP) loans from the US Government were taken out by at least 49 publicly traded bio/pharmaceutical companies from the $659bn loan program,...
Ferring Pharmaceuticals recently gained FDA approval for Milprosa, a once-weekly progesterone vaginal ring for the luteal phase support in women undergoing Assisted Reproductive Technology (ART)...
The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) declined by 10.1% during the week ended May 31, 2020...
The launch of the generic versions of dasatinib, following the expiration of Indian patent in April 2020 will increase the accessibility for treatment of chronic...
Following the news that India-based Sun Pharmaceutical Industries Ltd (Sun Pharma) has received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesylate in COVID-19 patients; Prashant...
At least 49 publicly traded bio/pharmaceutical companies took Paycheck Protection Program (PPP) loans from the US Government’s $659bn program despite official guidance that the money...
With a total of nearly 200,000 confirmed cases and over 5,500 deaths reported due to COVID-19 in the past three months, India stands in tenth position in...
As the global COVID-19 crisis continues, countries are taking stock of the current epidemiology information on the disease and attempting to evaluate if it is...
As of May 2020, six clinical trials for investigational medical marijuana products have been suspended as a result of COVID-19. Four of these trials had...
The Drug Controller General of India (DCGI) has recently given approval to Indian pharma companies Glenmark and Strides Pharma Science to initiate clinical trials of...
The US remains the most heavily affected country by the COVID-19 pandemic, with more than 1.7 million total confirmed cases. In comparison, South Korea is now thought...
In Japan, the plaque psoriasis (PsO) treatment landscape is highly competitive with the availability of conventional topical therapies, as well as biologics including anti-TNF, anti-IL-17, anti-IL-23 inhibitors, and...
As novel immuno-oncology (IO) drugs become established in the market, a new trend of combinatorial treatments is arising. The race to develop combinatorial drugs is...
The concept of an immunity passport is under scrutiny and it is crucial that the underlying scientific, ethical, legal and practical issues must be addressed...
The elderly and those with pre-existing conditions have now been drafted onto the front lines in order to restart economies as we face a balancing...
Novo Nordisk’s recent announcement of positive topline data from its Phase IIIa study STEP 4, investigating the use of semaglutide to treat obesity, will enable...
The clinical trial landscape has had multiple disruptions due to the COVID-19 pandemic, including the cardiovascular and metabolic disorder (CVMD) space. Despite a few trials...
As Gilead Sciences’ remdesivir continues to steal the COVID-19 spotlight, the antiviral is likely to be considered for inclusion in the top-secret US Strategic National...
Following the news that India-based BDR Pharmaceuticals has sought the Drug Controller General of India (DCGI)'s approval to manufacture and sell the generic version of...
The number of deals announced in the global healthcare sector grew by 0.6% during the week ended May 24, 2020 compared to the previous week,...
Although the number of clinical trials that have suspended enrolment due to COVID-19 is leveling off, the overall disruption of trials continues to expand, says...
Following the announcement that Novavax has agreed a $167m deal to acquire Praha Vaccines to aid its manufacturing capabilities for its Phase I COVID-19 vaccine...
Messenger RNA (mRNA) based vaccine technology is emerging as one of the frontrunners among the technologies being evaluated to develop a vaccine for COVID-19, with...
CytoDyn’s Leronlimab is a promising candidate for the treatment of COVID-19 and is currently forecast by GlobalData to have global peak sales of $747m in 2026...
Pharmaceutical software development has been less impacted by the COVID-19 crisis as it facilitates remote working and already had group collaboration tools and software processes...
A new report, published in Nature Reviews Drug Discovery, reveals that the cellular immunotherapy landscape continues to expand, with 472 more cellular therapies in development now...
Roche recently announced the Food and Drug Administration (FDA) approval of Tecentriq (atezolizumab) as a first-line monotherapy for the treatment of metastatic non-small cell lung...
As a result of the COVID-19 pandemic, the treatment access for opioid use disorder (OUD) may increase; Philippa Salter, Neurology Analyst at GlobalData, a leading data...
Following the recent news that Sunovion Pharmaceuticals has received Food and Drug Administration (FDA) approval for Kynmobi (apomorphine), a novel sublingual film for the acute...
Following the FDA’s safety review on sodium glucose-transporter-2 (SGLT-2) inhibitors, a label update was issued stating that patients undergoing any scheduled surgery should discontinue treatment...
The COVID-19 pandemic caused a decrease in childhood vaccinations as preventative care was disrupted by the pandemic. The lack of vaccination could lead to another...
Alexion is investigating monoclonal antibody treatments Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) as potential therapeutics for COVID-19. While these drugs have established safety data, they both...
Yale University launched a clinical trial of ibudilast (MN-166) to assess it as a treatment for COVID-19 patients with acute respiratory distress syndrome (ARDS), a...
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments...
The University of Oxford has reported positive findings from preclinical animal studies of its potential COVID-19 vaccine ChAdOx1, which involved nine rhesus macaques. The vaccine...
The diagnosed prevalent cases of angina pectoris is expected to increase from 19.58 million cases in 2018 to 22.79 million cases in 2028, at an...
Italy is a major active pharmaceutical ingredient (API) supplier to the global market, and its stringent lockdown measures has caused disruption of the supply chains that relied...
Following the announcement of Moderna’s interim data for its Phase I COVID-19 vaccine trial; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his...
Researchers from Washington University School of Medicine are now conducting a clinical trial of antidepressant drug fluvoxamine, as a potential treatment for the ‘cytokine storm’...
COVID-19 pandemic and opioid use disorder (OUD) are intersecting and worsening each other, demanding a rapid response to correct the underlying factors, says GlobalData, a...
In response to the global pandemic, biopharma companies have put a renewed emphasis on finding treatments for infectious diseases, including COVID-19 and other infectious diseases...
Clinical trials across the globe continue to be disrupted due to COVID-19. According to GlobalData, a leading data and analytics company, among global clinical trials that have been...
In the nine major pharmaceutical markets (9MM*), less than half of age-related macular degeneration (AMD) cases were diagnosed in 2019 in adults aged 50 years...
With the number of COVID-19 cases and deaths increasing with each passing day, the need for a therapeutic or a vaccine for the pandemic intensifies. Currently, 21...
As China opens up for businesses, the country is witnessing a new surge of travel-related COVID-19 cases in Jilin province in Northern China. The country had successfully...
With the scale and complexity of cybercrime increasing, and the fact that hospitals are moving toward digitalization and remote patient care, the number of cyberattacks...
A study by Sama et al. published in the European Heart Journal found that the ACE2 concentrations in heart failure patients are not affected by...
The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) grew by 4.4% during the week ended May 10, 2020...
Targeted therapies have delivered on their promise to make oncology more personalized. However, the addition of immunotherapy agents without first testing for patients who are...
Following the news that Indian Council of Medical Research (ICMR) and India-based Bharat Biotech have partnered to develop an indigenous COVID-19 vaccine; Anupama, Pharma Analyst at GlobalData, a...
In 2019 the US Food and Drug Administration (FDA) accepted 119 New Drug Approvals (NDAs) and Biologics License Applications (BLAs) including New Molecular Entities (NMEs)...
With Fujifilm Toyama Chemical’s Avigan (favipiravir) already approved in Japan for influenza, that country had announced plans to stockpile two million courses of the oral drug for...
Cerus Endovascular’s secured CE approval for coil-assisted flow diverter Neqstent was a great win for the company, but the path ahead may be slow-going. GlobalData,...
Following the news that Moderna’s mRNA COVID-19 vaccine candidate received FDA approval to start Phase II clinical studies; Philipp Rosenbaum, PhD, Infectious Diseases Analyst at GlobalData,...
A significant increase in the total prevalence of PTSD is expected globally amid the COVID-19 pandemic - with the risk for women being twice as...
As the COVID-19 pandemic continues to spread, researchers are examining reasons why various countries were impacted differently. It has been suggested that the severity of...
In April, Eli Lilly joined the fight in treating COVID-19 with an announcement that it had agreed to study Olumiant (baricitinib) as an arm in...
More than half of the top 20 global innovative pharma companies by market cap (Mcap) value saw a decrease in their MCap in the first...
Japan has already witnessed a significant downturn in the number of new daily COVID-19 cases since the national emergency was declared. However, the country is likely to see...
Despite the COVID-19 outbreak, China managed to launch its national blockchain-based service network (BSN) in April 2020, as scheduled earlier, in an attempt to promote the mass...
The unprecedented events of the past few months have upended societies and healthcare systems alike. With the increased need for medical innovation and research to...
The Department of Science and Technology - Science and Engineering Board (DST-SERB) has recently initiated several special research projects. These efforts could help contain community spread of the...
Recent results have shown that high-dose chloroquine has potential safety concerns resulting in QTc prolongation, a heart rhythm disorder that serves as a surrogate indicator...
The COVID-19 pandemic is set to impact the pharmaceutical industry in a profound way, according to GlobalData, a leading data and analytics company. From postponed...
Following the news that India has approved nearly US$2bn* towards ‘India COVID-19 Emergency Response and Health System Preparedness Package’; Sasmitha Sahu, Pharma Analyst at GlobalData, a leading data...
A survey conducted by GlobalData between 6 April and 20 April about the use of telemedicine during the COVID-19 crisis saw an overwhelming majority of...
Cereno Scientific’s preclinical candidate CS-1 (valproic acid) was recently granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) for the US market for pulmonary arterial hypertension (PAH)...
Regeneron and Sanofi recently announced the preliminary results from the Phase II portion of an ongoing Phase II/III trial evaluating Kevzara (sarilumab), an antibody targeting...
With an unexpected spike in COVID-19 cases, India has extended the countrywide lockdown till 17 May 2020. The move reflects India’s dependency on lockdown to contain the pandemic...
Organizations are relying on real-world evidence (RWE) to help tcontain the spread of COVID-19. Real-world data can provide valuable insights to help organizations better understand,...
Start-up companies in the UK are turning to artificial intelligence (AI) for analysis of existing drugs and new molecules. The use of AI in this...
The fast-paced adoption of digital technologies is emerging as a key element of remodeling healthcare delivery and scaling up systems. While the risk-averse culture, legacy...
As COVID-19 spreads through the global population, the rate of hospital admissions increases daily and threatens to overwhelm health systems. Certain patient populations have been...
With the EMA announcing today that it will start a rolling review of Gilead Sciences’ remdesivir for COVID-19 and wide expectations that US Emergency Use Authorization (EUA)...
The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) grew by 12.3% during the week ended April 26, 2020...
Pharmaceutical industry professionals around the world believe that employee safety and supply chain disruption are their businesses’ number one concerns from COVID-19, the latest survey...
The COVID-19 pandemic that has swept the globe has led to a massive search for a drug with which to combat this deadly virus. Yet,...
People with severe obesity, defined as having a body mass index (BMI) of 40 or higher, are now considered to be at risk for developing...
Concerns have arisen that treatments for cancer patients could be affected by shortages in cancer drug supply and distribution as valuable medical resources are being...
As the COVID-19 global pandemic grows with the UK, active inflammatory bowel disease (IBD) patients could be at a higher risk, as patients using prominent therapies...
Following the news that India-based Strides Pharma has developed and commenced the export of generic favipiravir antiviral tablets to potentially treat COVID-19 infection; Sasmitha Sahu, Pharma Analyst at GlobalData, a...
Following the announcement that SeaStar Medical will initiate a pilot study of aselective cytopheretic device (SCD) in COVID-19 patients; Azadeh Laffafian, Medical Device Analyst at GlobalData,...
Interest in a class of drugs called JAK inhibitors to manage COVID-19 is building, and with three such therapies already approved for other diseases, the...
As the COVID-19 pandemic continues, pharmaceutical companies are working on finding treatments to lessen the symptoms of the disease. Several drugs are being investigated for...
India-based Wockhardt Ltd has recently received US FDA qualified infectious disease product (QIDP) status for WCK 677 (currently filed Investigational New Drug Application/Clinical Trial Application (IND/CTA)) to...
The rheumatoid arthritis (RA) treatment landscape in Japan is highly competitive with many novel disease-modifying anti-rheumatic drugs (DMARDs). To stay ahead of the competition, the branded support offered...
Following the news that Gilead’s antiviral remdesivir has met its primary endpoint in a clinical trial run by the National Institute of Allergy and Infectious...
Propeller Health, a respiratory digital health company, released data last week showing that asthma and COPD patients have become more adherent to their medication since...
Free goods movement restrictions, imposed by the majority of EU countries at their borders to control the spread COVID-19, are disrupting supply chains, including crucial...
Roche’s Actemra (tocilizumab) generated $687m in the first quarter of 2020, a 30% increase compared to the same period in 2019, due to evidence of...
Following the news that the launch of Neurocrine Biosciences’ Ongentys (opicapone) has been delayed due to the disruption caused by COVID-19, after receiving Food and...
As the COVID-19 pandemic continues, developing a vaccine for the disease becomes a pressing manner, but a reasonable time frame for accomplishing a working vaccine...
India-based Natco Pharma has recently launched a generic version of AstraZeneca’s patented anti-diabetes drug Forxiga (dapagliflozin). Natco’s sodium glucose co-transporter-2 (SGLT2) inhibitor, Dapnat, is indicated for the treatment...
As the COVID-19 pandemic continues to spread, understanding how the differences in each countries response to the situation affected the outcome of the spread of...
Clinical trials evaluating pain and mental health conditions are the neurology indications most affected by the ongoing COVID-19 pandemic, says GlobalData, a leading data and...
Up to 80% of COVID-19 cases are mild or asymptomatic and therefore unlikely to be diagnosed. Determining what percentage of the population is asymptomatic will...
Following the news that President Trump discussed in a press conference how UV rays and certain disinfectants may kill the coronavirus,Johanna Swanson, Product Manager at...
The European Union needs more solidarity and coordinated actions to effectively respond to the COVID-19 outbreak, says GlobalData, a leading data and analytics company. Urte Jakimaviciute,...
Following the news that China trials of Gilead Sciences Inc’s antiviral drug remdesivir in patients with mild symptoms of coronavirus (Covid-19) have been suspended due...
Following the Food and Drug Administration’s (FDA) authorization of the first COVID-19 diagnostic test with a home-collection option; Aliyah Farouk, Medical Device Analyst at GlobalData, a...
The majority of the top 20 global innovative pharma companies, identified by GlobalData, declined in market cap (MCap) in Q1 2020 (quarter ended 31 March...
Austerity measures, dissatisfaction with politics, lack of transparency in the EU’s decisions and uncontrolled immigration may have been the major factors influencing the Brexit vote....
A total of 892 deals were announced globally during the week ended 19 April, 2020, which is a decrease of 0.8% over 899 deals announced...
Preliminary results for the Phase II study for high dose chloroquine disphosphate (CQ) for COVID-19 patients showed hazardous side effects of a QTc prolongation, resulting...
The UK National Health Service (NHS) has been forced to rapidly adapt its digital stance in the fight against the COVID-19. These digital shifts are...
Following the announcement that Renalytix AI’s KidneyIntelX™ platform will be used to assess the risk of kidney injury in COVID-19 patients;Azadeh Laffafian, Medical Device Analyst at...
As the COVID-19 pandemic spreads rapidly throughout the world, the urgency of finding a treatment has magnified. The Coronavirus Treatment Acceleration Program (CTAP), a special...
Emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with high unmet need, according to GlobalData, a leading data and...
Regulatory bodies worldwide are taking action to combat COVID-19. In Europe, the European Medicines Agency (EMA) has established the COVID-19 EMA pandemic Task Force (COVID-ETF), which...
With the continuation of the COVID-19 pandemic and possible vaccines approximately one year away from launch, the race to find a treatment for the disease...
As the COVID-19 pandemic continues to spread, collaborations between companies with differing areas of expertise could accelerate the availability of a treatment for the disease....
In response to the COVID-19 pandemic, a large-scale randomized clinical trial is to initiate in the UK to assess some of the potential treatments for...
Several companies developing mesenchymal stromal cells (MSCs) for COVID-19 saw significant stock movement after announcing their plans, and early data is indeed encouraging for further...
The Biomedical Advanced Research and Development Authority (BARDA) has agreed to provide up to $483m to assist Moderna in developing its COVID-19 vaccine candidate, but reporting...
The American Society of Reproductive Medicine (ASRM) issued guidance on fertility treatments during COVID-19 and called for suspension of most new treatment cycles such as...
Novartis’ Isturisa (osilodrostat) leads recent innovation in Cushing’s disease (CD) with its latest Food and Drug Administration (FDA) approval, says GlobalData, a leading data and...
With the accelerating global burden from the COVID-19 pandemic, researchers are rapidly searching for a viable vaccine or therapeutic to combat the global public health...
A number of pharmaceutical companies have RNA-based therapeutics and vaccines in development for COVID-19. However, there are a number of safety concerns around the use of viral vectors with...
India-based Curadev’s licensing agreement with Bayer in March 2020 for the discovery and development of novel stimulator of interferon genes (STING) antagonists across indications with high unmet...
AbbVie was one of the first companies to donate its combination of HIV protease inhibitors Aluvia (lopinavir/ritonavir), also known as Kaletra, to help China treat patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)....
The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) declined by 28% during the week ended April 12, 2020 compared to the previous week, according to GlobalData’s deals database. Aurojyoti Bose, Analyst at GlobalData, comments: “The decline was subsequent to two...
The pharmaceutical market for age-related macular degeneration (AMD) was worth an estimated $8.6bn across the nine major markets (9MM*) in 2018. This is expected to grow to $18.7bn in 2028 at a modest compound annual growth rate...
India's coronavirus (Covid-19) lockdown has impacted the manufacturing and supply chain operations of pharmaceuticals despite pharmaceutical manufacturing being considered an essential service and excluded from the lockdown. However,...
Following the news that AstraZeneca’s Koselugo (selumetinib) has been approved by the US Food and Drug Administration (FDA) for the treatment of a rare neurological...
A comparison analysis of COVID-19 deaths from seven major markets (7MM*) shows disproportionate rates among older age groups says GlobalData, a leading data and analytics...
With the global COVID-19 pandemic, many patient groups are at an increased risk of infection and this extends to rheumatology patients prescribed immunosuppressant medication. The...
There has been an overall increase in clinical trials that have pushed back their estimated start dates since the beginning of January 2020, largely due...
With many countries putting clinical trials studies on hold, pharmaceutical companies are shifting their overall priorities away from some current indications toward COVID-19. This could...
Novartis has taken a lead in actively promoting heart failure awareness across India through unbranded digital initiatives that can successfully deliver message to a large population at risk,...
Biomarkers are a beneficial tool in the search for a COVID-19 vaccine and will help speed up clinical trials, reduce costs of development, guide subject...
Novo Nordisk will continue to dominate a large share of the glucagon-like peptide-1 receptor agonist (GLP-1RA) market with the arrival of Rybelsus and Ozempic’s strong global sales of $1.65bn in 2019. This will enable the company to maintain its well-established position in the wider diabetes market, according to GlobalData, a leading data and analytics company. Akash Patel...
Use of virtual mental health tools is expected to rise significantly over the coming months as self-quarantine and social distancing measures show no signs of being lifted, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc,...
As the number of confirmed COVID-19 cases reaches nearly 1.5 million worldwide, with almost 430,000 in the US alone, the urgency of finding a treatment mounts. One of...
As the COVID-19 pandemic grows across the world, companies are beginning to accelerate their clinical trials for therapeutics and the number of trials has been...
There has been an increase in clinical trial delays due to concerns for patient and investigator safety, travel restrictions, subject quarantine, clinical site closures and...
The COVID-19 pandemic has disrupted nearly every part of supply chains within the healthcare industry, once again exposing the vulnerabilities of many organizations, especially those...
Gilead Sciences’ remdesivir is more likely to work in mild-to-moderate COVID-19 patients rather than severe cases, according to reporting from Reynald Castañeda, Pharma Writer for the Investigative...
Following the news that the continual disruption caused by COVID-19 is starting to have an impact on the drug development programme timings of leading pharma...
Given the speed and rapidity of spread of the COVID-19 epidemic, identifying already available compounds to use on patients has the promise of being able...
With the advent of COVID-19 reaching over one million cases worldwide, a concerted effort will be needed to approach this growing problem. Drug development partnerships...
As COVID-19 spreads, the search for a treatment is ramping up. The antimalarial and immunosuppressant hydroxychloroquine has received some attention, including that of President Trump. There are currently around 60 planned...
In this unprecedented time of uncertainty, key markets have lost 20–70% of their value year-to-date due to COVID-19, according to GlobalData’s COVID-19 Executive Briefing. Sharon Cartic,...
Coronavirus (COVID-19) has now spread across 184 countries with approximately 1.5 million total confirmed cases worldwide as of 09.04.2020;Katie Wrenn, Associate Epidemiologists at GlobalData, a leading data...
As the COVID-19 situation grows, intensive care units (ICUs) in hospitals have to handle more patients with severe cases of the virus. COVID-19 can be...
It is likely that Italy has reached a peak in COVID-19 transmissions as the country has seen a continued decrease in new laboratory-confirmed cases for...
According to new guidelines published by the US Preventive Services Task Force (USPSTF), hepatitis C virus (HCV) screening will now expand to include all adults ages 18 to 79...
Following the introduction of social distancing measures, brought in to reduce the spread of COVID-19 across the globe;Emily Carter-Richardson, Pharma Analyst at GlobalData, a leading...
From Francis Collins’ tweet on the NIH clinical trial of an investigational vaccine for COVID-19 to the flu and coronavirus striking at the same time, leading data...
In the race to find treatments for COVID-19, repurposing therapies already approved for other indications to fight the SARS-CoV-2 virus is one key strategy. Approved...
The market for graft versus host disease (GvHD) prophylaxis and treatment in the seven major markets (7MM*) will undergo rapid growth, at a compound annual growth rate...
Alexion Pharmaceuticals is revving up to enter the COVID-19 drug development race with Soliris (eculizumab), a drug that is already approved for other indications, a source...
An estimated 1.5 billion people around the world have been asked to practice social distancing amid the outbreak of coronavirus (COVID-19) that has caused the...
While checkpoint inhibitors as monotherapies have fulfilled expectations in some indications, novel combinations are on the horizon in a broader range of cancers says GlobalData,...
In the key markets most heavily affected by the coronavirus (COVID-19), case trends are expected to follow a low-risk forecast, with the exception of the...
COVID-19 has a significant impact on patients with pre-existing conditions, many of which fall under the cardiovascular (CV) and metabolic disorder (CVMD) category. The current...
India’s agility so far in handling the coronavirus (Covid-19) situation is an exemplar, given its large population and the public healthcare challenges. As the country gears up...
Thepneumococcal vaccines market is expected to grow from $5.11bnin 2018 to $6.24bnin 2028across the nine major markets (9MM*) at a compound annual growth rate (CAGR)...
Thus far, the novel coronavirus (COVID-19) pandemic has surpassed 860,000 confirmed cases globally and while the economic impact is weighing heavily across sectors, organizations are exploring creative ways of how to combat the outbreak. The responses are not only fighting COVID-19, supporting the general public and propping up the healthcare system,...
Of the more than 230 nanopharmaceuticals in clinical development, 75% are for oncology indications, including many hard-to-treat cancers with few treatment options, according to GlobalData, a leading data and analytics company. Nanopharmaceuticals have many physical and biological advantages...
Following the news that Intarcia has received a second rejection from the Food and Drug Administration (FDA) regarding its subcutaneous osmotic pump implant, ITCA 650, for type 2 diabetes (T2D) patients; Akash Patel MSc, Pharma Analyst...
Following a number of recent global news stories about viral load and its impact on Coronavirus (COVID -19) patients; Michael Breen, Director of Infectious Diseases at GlobalData,...
As the novel coronavirus (COVID-19) pandemic continues to spread globally, virtual platforms will experience an extra boost after already having a transformational impact on the...
Despite the plethora of drugs currently available for patients with psoriatic arthritis (PsA), several key unmet needs remain, according to GlobalData, a leading data and analytics company.The company’s report: ‘Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028’ reveals...
The FDA recently lifted an import ban it had imposed in 2015 on India’s Ipca Laboratories due to quality issues and non-adherence to good manufacturing...
India has recently sought feedback from the top pharmaceutical companies to make regulatory changes that offer specific tax benefits for specialized research. With the government’s inclination towards promoting...
The value of the US transcatheter mitral valve repair (TMVR) device market was just over $250m in 2019 and is set to be worth $1.4bn by 2028...
Novartis recently announced new anticipated long-term positive data for its one-time infusion gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), which is set to help the drug generate global...
Following the recent news that the coronavirus (COVID-19) has now spread across 176 countries with approximately 530,000 total confirmed cases worldwide as of 27.03.20; Katie Wrenn, Associate...
Invasive pneumococcal disease (IPD) presents a significant public health concern globally. India leads the way with the highest number of diagnosed incident cases of IPD, says GlobalData, a...
As the number of global coronavirus (COVID-19) cases continues to rise, governments around the world are taking unprecedented measures, to contain the spread and support their economies...
With several mega cap biopharma companies having their vital manufacturing steps in Chinese facilities, the novel coronavirus (Covid-19) outbreak is putting the complicated global biopharma industry's supply chain...
Following the news that India has approved US$1.3bn* (INR10Kbn) healthcare package to boost the domestic manufacturing of active pharmaceutical ingredients (API); Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and...
Last week, the GlobalData epidemiology team conducted a three-scenario forecast model of the coronavirus (COVID-19) transmission in the US, with the moderate estimate projecting more...
The current multiple sclerosis (MS) pipeline is strong and diverse with a total of 49 products in all stages and phases of clinical development. However,...
The Asia-Pacific (APAC) has emerged as the most prominent region for conducting clinical trials, accounting for over 40% of the annual share of globally conducted clinical trials in...
Synairgen has received approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled...
Use of telemedicine in the US has been low to date. However, it is expected that demand for these services will increase dramatically over the...
The axial spondyloarthritis (axSpA) market across the five growth markets (5GM*) in the Asia-Pacific (APAC) region will experience moderate growth over the next 10 years,...
There has been an exponential increase of coronavirus (COVID-19) cases in the US since the beginning of March, from less than 70 to more...
Tessa Therapeutics’ TT11 has become the first CAR-T therapy to receive the Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation and is set to become...
Microvascular angina (MVA) is being increasingly recognized in clinical practice, says GlobalData, a leading data and analytics company. According to key opinion leaders (KOLs) interviewed by...
The impact of the coronavirus (Covid-19) outbreak on industries ranging from technology to automotive has been the subject of intense analysis in the recent months. This has...
Diagnosed incident cases of renal cell carcinoma (RCC) in the eight major markets (*8MM) are projected to increase from 0.20 million cases in 2018 to...
Following the news that MedDay Pharmaceutical’s MD1003 for the treatment of non-active progressive forms of multiple sclerosis (MS) failed in a Phase III clinical trial; Philippa...
Covid-19 transmission in China is reportedly winding down as reported new cases are decreasing, but the virus is just starting to make the rounds in...
Following the recent news that The Drug Controller General of India (DCGI) has approved Zydus Cadila’s new drug application (NDA) for Lipaglyn (saroglitazar) for treatment...
The numbers of breast cancer cases in men are growing steadily in the US. Epidemiologists at leading data and analytics company GlobalData forecast an increase...
Out of all the drugs that are currently in the pre-registration phase and are expected to launch in 2020, ten have the potential to reach...
The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market is expected to grow from $935.9M in 2018 to $1.6bn by 2028 across the seven...
The financial burden of diagnosed bladder cancer is expected to grow between 2018 and 2028 in the seven major markets (7MM)* due to an increase...
vTv Therapeutics recently announced positive Phase 2 results for its oral antidiabetic drug, TTP-399, when used as an adjunct therapy to insulin in type 1...
The statement from the World Health Organization (WHO) that we are in “uncharted territory” on the coronaries outbreak comes as no surprise as Covid-19 infections...
The bladder cancer market is expected to significantly grow from $733m in 2018 to $4.0bn by 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 18.5%, according to GlobalData, a leading data and...
Gut bacteria research is seeing a resurgence in drug development, including beyond gastrointestinal disorders, with pharmaceutical companies diving into microbiome-focused cancer therapeutic candidates. Experts, however,...
Digital marketing in pharma is gaining increasing importance in recent times and Indian multinational pharmaceutical company Cipla Limited can be termed as a pioneer in this space from...
The financial burden of diagnosed bladder cancer is expected to grow between 2018 and 2028 in the seven major markets (7MM)* due to an increase...
There are currently 445 chimeric antigen receptor (CAR-T cell) therapies under development by companies headquartered across the Asia-Pacific (APAC) region. With research in progress and increased understanding of...
As patients, clinicians and researchers prepare for Rare Disease Day on February 29 2020, GlobalData’s analysis shows the number of drugs awarded orphan drug designations...
Agile Therapeutics’ Twirla (ethinyl estradiol + levonorgestrel) could have an edge over competitors based on milder side-effects and a potentially safer profile, says GlobalData, a leading data and analytics company. As the largest contraceptives market,...
Following today’s news that Clover and GSK have announced a research collaboration to evaluate a coronavirus (COVID-19) vaccine, and also that the US government wants...
Following the news that the Food and Drug Administration (FDA) has approved Vyepti for the prevention of migraines in adults, Philippa Salter, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Vyepti becomes the latest FDA approved drug for prevention of migraines in adults, following the approval of Amgen’s Aimovig, Eli Lilly’s Emgality and...
Current treatment options for dry eye syndrome (DES) are limited to artificial tears, mostly on its own for milder forms of DES and in combination with anti-inflammatory and corticosteroid therapies for more severe forms of DES. However, this treatment paradigm is expected to see...
The dermatophytic onychomycosis market is expected to grow from $208.8m in 2018 to $676.4m in 2028 within the US, at a compound annual growth rate...
